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Preface
Remarkable advances have been achieved in the elucidation of the mechanisms 
of involvement of biogenic amines in neurotransmission and human disease. 
In this book, we briefly review neurotransmission, novel therapeutic options in 
neurodegeneration, thrombotic tendencies in catecholamine excess states, and the 
pharmacological potential of plant herbs in dealing with catecholamine associated 
stress. In the introductory chapter, I summarize the physiology of neurotransmis-
sion and describe how biogenic amine excess is associated with human disease, 
with the example of pheochromocytomas and paragangliomas. In the second 
chapter, Dr Rodriguez-Moreno describes the latest knowledge on kainate receptors 
and how they modulate glutamate release in the cerebellum, also presenting some 
insight on how aberrations in the described pathways relate to human disease. In 
the third chapter, Prof. Martin-Aragon describes the recent advances in the thera-
peutic management of neurodegenerative diseases, also giving some insight into 
homeostatic plasticity, which refers to the capacity of neurons to regulate their own 
excitability relative to network activity, a compensatory adjustment that occurs over 
the timescale of days. Therapies to modulate neuronal plasticity to halt neurode-
generation and their related clinical findings have shown much progress in the last 
decade, with enhanced understanding of neurobiology and molecular genetics that 
now allow genome editing that has the potential to halt the progress of neurodegen-
eration. In the fourth chapter, Prof. Nobuyuki presents information on the potential 
effects of plant herbs in alleviating the stress induced by catecholamine signaling. In 
the last chapter, the mechanisms regarding thrombotic tendencies in catecholamine 
excess are covered by Dr Rajan. The last two chapters succinctly describe how 
catecholamine excess states are associated with derangements in multiple systems in 
the human body.
I hope this book will serve as a point of reference and source of inspiration for 
researchers and clinicians interested in addressing issues regarding biogenic amine 
excess- or deficiency- related diseases in humans.
Ahmet Uçar, MD
Associate Professor,
University of Health Sciences,
Şişli Hamidiye Etfal Education and Research Hospital,
Istanbul, Turkey
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Introductory Chapter:  
Biogenic Amines in 
Neurotransmission and Human 
Disease from the Endocrinologist’s 
Perspective
Ahmet Uçar
1. A synopsis of the normal physiology of neurotransmission in man
There are about 1011 neurons and 1014 synaptic connections in the human brain. 
The neural circuitry is continuously sculpted in response to experience, modified as 
we learn and store memories, and irreversibly altered by the gradual loss of neurons 
and connections as we age [1].
Neuronal signals are transmitted from cell to cell at synapses. When an action 
potential arrives at the presynaptic site, the depolarization of the membrane opens 
voltage-gated calcium channels that are clustered in the presynaptic membrane. 
Calcium influx triggers the release of neurotransmitters which are stored in mem-
brane-enclosed synaptic vesicles and released by exocytosis. The neurotransmitter 
provokes an electrical change in the postsynaptic cell by binding to and opening 
transmitter-gated ion channels. After the neurotransmitter is secreted into the 
synaptic cleft, it is rapidly removed: it is either destroyed by specific enzymes in 
the synaptic cleft or taken up by the presynaptic nerve terminal or by surrounding 
glial cells. Reuptake is mediated by a variety of Na+-dependent neurotransmitter 
symporters. The cycling of neurotransmitters allows cells to keep up with the high 
rates of release [1–3].
The chemical or electrical synapses can be excitatory or inhibitory. Excitatory 
neurotransmitters open cation channels, causing an influx of Na+ and also Ca+ 
in many cases, which reduces the threshold to fire an action potential. Inhibitory 
neurotransmitters open Cl− or K+ channels, thereby making it difficult to depolarize 
the cell membrane. Depending on the secretion milieu, the type of the receptors 
they bind to, and the ionic conditions that they encounter, transmitters may be 
either inhibitory or excitatory. For example, acetylcholine may have inhibitory or 
excitatory effects depending on the type of the receptor it binds to. Usually glu-
tamate and serotonin are excitatory, whereas γ-aminobutyric acid and glycine are 
inhibitory [1–4]. All neurotransmitter receptors fall into one of these classes based 
on their signaling mechanisms:
1. Ionotropic receptors—ion channels present at fast chemical synapses. 
Example: acetylcholine receptor of skeletal muscle cells is a transmitter-gated 
ion channel which is opened transiently by acetylcholine released from the 
nerve terminal at a neuromuscular junction.
1
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2. Metabotropic receptors—also called G protein-coupled receptors. Signaling 
via is these receptors is somewhat slower, more complex, and longer lasting in 
its effects. For example: hormones such as parathyroid hormone operate via G 
protein-coupled receptors [1].
Biogenic amines such as dopamine, norepinephrine, serotonin, and histamine 
manifest their effects either directly or indirectly via their specified receptors [1].
2. Biogenic amines in human disease
Any dysfunction that occurs in the aforementioned physiological setups in 
the organism may be associated with a disease state, mostly with neurological 
consequences, and therapy is aimed at inducing the recovery of the dysfunctional 
pathway via drugs or, most recently, the gene therapy, which is elaborating ground-
breaking results [5].
Disorders of neurotransmission in the human are either due to the lack of synthesis 
of the neurotransmitter, disordered synapse due to external insults such as trauma, 
autoimmunity, or impaired or enhanced receptor-ligand interaction at the postsynaptic 
area. The list of the neurogenerative diseases, the inborn errors of metabolism associated 
with dysfunctional neurotransmission, is not exhaustive and is discussed elsewhere [6].
From the endocrinologist’s perspective, excess of biogenic amines includes many 
rare endocrine neoplasias such as pheochromocytomas (PHEO) and paraganglio-
mas (PGL). The carcinoid syndrome, a constellation of clinical symptoms of bio-
genic amine excess particularly of serotonin, is much rarer in clinical practice, and 
it is usually observed in the context of clinically manifest neuroendocrine tumors, 
such as midgut carcinoids. In the pediatric patient, these syndromes of amine excess 
are usually associated with hereditary syndromes of endocrine neoplasia, such as 
von Hippel-Lindau disease and multiple endocrine neoplasia (MEN) type 2 syn-
drome, whereas sporadic cases are more common in the adult [7]. The diagnosis of 
amine excess states is challenging since single measurement of the culprit molecules 
via standard laboratory tests is often inconclusive and full of caveats that mandate 
repeat measurements of the suspected amines and/or their metabolites. Below is 
a brief description of catecholamine excess related tumors as an example to how 
biogenic amine excess may relate to human disease.
Pheochromocytomas and paragangliomas (PGL) are uncommon neuroendo-
crine tumors of neural crest origin, with the former being of adrenal medulla origin 
and the latter originating from sympathetic and parasympathetic system. All func-
tional PHEO/PGL produce and metabolize catecholamines and contain chromaffin 
tissue, which refers to the brownish black color due to oxidation of catecholamines 
after staining with chromium salts. Pheochromocytomas comprise the majority of 
the tumors in the pediatric patient [7].
Dopamine, norepinephrine, and epinephrine are biogenic amines collectively 
referred to as catecholamines. These neurotransmitters and hormones are involved in 
regulation of numerous physiological processes and development of neuropsychiatric 
and cardiovascular diseases. They are synthesized from tyrosine, which is converted 
to 3,4-dihydroxyphenylalanine (DOPA) by the enzyme tyrosine hydroxylase, the 
rate-limiting enzyme in catecholamine synthesis. Decarboxylation and hydroxylation 
of dopa yield dopamine and norepinephrine, respectively. Norepinephrine is then 
converted to epinephrine via the enzyme phenylethanolamine N-methyltransferase.
The complex actions of norepinephrine and epinephrine are mediated by the G 
protein-coupled alpha- and beta-adrenergic receptors, whereas dopamine binds to a 
different class of metabotropic receptors.
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The clinical presentation PHEO/PGL is variable. Owing to the neuroendocrine 
origin, they might co-secrete other hormones that result ectopic hormone excess, 
such as gigantism due to growth hormone-releasing hormone, hypercalcemia due 
to parathyroid hormone-related peptide, or secretory diarrhea due to vasoactive 
intestinal peptide. The clinical symptoms and signs of functional PHEO/PGL also 
depend on differences in catecholamine secretion and release as individual patient 
sensitivities to catecholamines. Signs of catecholamine excess include hyperten-
sion, headaches, palpitations, diaphoresis (less common in children), orthostatic 
hypotension, pallor, tremor, and anxiety. Depending on the location of the tumor, 
nonspecific signs and symptoms include blurred vision, abdominal pain, diarrhea, 
or behavioral problems/decline in school performance [7].
The diagnosis of excess catecholamine secretion due to PHEO/PGL has been 
facilitated by the development of assays sensitive to diagnose these entities; mea-
surements of fractionated metanephrine and normetanephrine in plasma and urine 
are considered the primary diagnostic tests in the initial evaluation of suspected 
PHEO/PGL. An elevation of metanephrines greater than fourfold above the refer-
ence range is considered indicative of a catecholamine secreting tumor [8]. It should 
be noted that some PGL can be nonfunctional and may be diagnosed incidentally or 
due to clinical signs and symptoms owing to their anatomical position, as is the case 
in some paragangliomas of the head neck which arise from parasympathetic gan-
glia. Catecholamine-secreting tumors may be noradrenergic as in tumors associated 
with von Hippel-Lindau disease and familial PGL or adrenergic as seen in tumors 
that arise sporadically or in the context of MEN type 2 and neurofibromatosis type 
1. Dopamine-secreting tumors are very rare and typically extra-adrenal succinate 
dehydrogenase-mediated paragangliomas. Measurement of methoxytyramine may 
be of help in this context, but the test is not widely available [9]. Chromogranin A is 
also another effective tumor marker that may correlate with tumor size and malig-
nant potential.
Radiographic studies and in selected cases, molecular genetic testing should be 
planned once the diagnosis of catecholamine secreting tumor is highly considered. 
Further information on management of PHEO/PGL is discussed elsewhere [7].
The expanding knowledge on synthesis and function of biogenic amines may 
pave the path for enhanced medical treatment of disease states of owing to biogenic 
amine excess. Recent studies have also shown that biogenic amines have additional 
important roles as signaling molecules mediating the function of the “microbiota-
brain-gut” axis [10]. The potential role of biogenic amines in this axis is an exciting 
new area of medicine that awaits for further studies.
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Kainate Receptors Modulating 
Glutamate Release in the 
Cerebellum
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Abstract
Glutamate receptors of the kainate type (Kainate receptors, KARs), are media-
tors of ionotropic postsynaptic synaptic transmission, as well as presynaptic 
modulators of neurotransmitter release where they show both ionotropic and 
metabotropic actions regulating glutamate and γ-aminobutiric acid (GABA) release. 
The mechanisms underlying these modulatory roles are starting to be understood at 
some brain regions. Here we review the KARs roles and mechanisms involved in the 
modulation of glutamate release in the cerebellum at parallel fibers (PF)-Purkinje 
Cells (PuC) synapses. KARs activation mediate a biphasic effect on glutamate 
release at this synapse, with low kainate (KA) concentrations mediating a facilita-
tion of glutamate release and higher KA concentrations mediating a depression of 
glutamate release. KA-mediated facilitation is prevented by antagonizing KARs, 
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Alzheimer’s disease, Huntington’s Korea, amyotrophic lateral sclerosis, Parkinson’s 
disease, hypoglycemia, or cerebral ischemia [1–3].
Glutamate receptors are classically divided into two large families: ionotropic 
and metabotropic. Ionotropic glutamate receptors (iGluRs) participate in rapid 
neurotransmission in the nervous system; these ionotropic receptors are classified 
into three types depending on the agonist that activates them with higher affinity: 
N-methyl-d-aspartic acid (NMDA) receptors (NMDARs), α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA) receptors (AMPARs), and kainate 
receptors (KARs). These receptors form a channel with different selectivity 
depending on their subunit composition, all of them being permeable to Na+ and 
K+ and, additionally, NMDARs are permeable to Ca2+ been some AMPARs and 
KARs also permeable to Ca2+ depending on subunit composition. They are inte-
gral membrane proteins, formed by four subunits (tetramers), being homomers 
or heteromers [1, 2].
Metabotropic glutamate receptors (mGluRs), which participate also in 
neurotransmission, are coupled to G proteins and are divided into eight types 
(mGluR 1–8) and three groups of receptors: group I mGluRs includes mGluR1 
and mGluR5 receptors. These receptors are positively coupled to phospholipase C 
(PLC), which facilitates the conversion of inositol diphosphate (PIP2) to diacyl-
glycerol (DAG) and inositol triphosphate (IP3). DAG activates protein kinase C 
(PKC) that phosphorylates different substrates and IP3 causes numerous intra-
cellular effects, including the facilitation of Ca2+ release from intracellular stores. 
Group II mGluRs includes mGluR2 and mGluR3 receptors. These receptors are 
negatively coupled to adenylate cyclase-mediated AMPc formation, and group 
III mGluRs includes mGluR4, mGluR6, mGluR7, and mGluR8 receptors. These 
receptors are negatively coupled to the formation of AMPc mediated by adenyl-
ate cyclase [4].
1.1 Kainate receptors
Kainate (KA) is a potent neurotoxin derived from the alga Digenea simplex. The 
word “Kainic” is derived from the Japanese “Kaininso” (“Makuri”), which means 
“the ghost of the sea,” and it is an agonist for both KARs and AMPARs (in the same 
way that the AMPARs agonist AMPA may activate KARs). Kainate is classically 
known for its potent epileptogenic actions [5, 6].
KA (and other agonists) activates KARs that are tetramers that resulted from 
different combinations of five subunits called GluK1, GluK2, GluK3, GluK4, and 
GluK5 (formerly known as GluR5, GluR6, GluR7 and KA1, and KA2, respectively). 
Of these subunits, GluK1 and GluK3 may form homomeric or heteromeric func-
tional receptors, while GluK4 and GluK5 may only participate in functional recep-
tors when associated with any of the GluK1, GluK2, or GluK3 subunits, but they do 
not combine with subunits of AMPARs [1, 7, 8].
KARs have been described in different invertebrates such as nematodes and 
flies [9, 10] and in different species of vertebrates such as amphibia, fish, and birds 
[11–13] in addition to mammals. In mammals, KARs have been observed virtually 
throughout the entire nervous system, although their subcellular location has not 
been yet fully determined. KARs are widely distributed throughout the CNS and 
found in the main cells and interneurons of the hippocampus, lateral amygdala, 
dorsal root ganglia, bipolar cells of the retina, cerebral cortex, and the cerebellum 
[14, 15].
The lack of knowledge about these receptors compared to other glutamatergic 
receptors (AMPARs or NMDARs) has been due to the lack of good agonist and 
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antagonist for receptors with particular subunit compositions and to the absence of 
specific antibodies for the different subunits of KARs, being therefore a significant 
limitation when exploring the distribution of these receptors. However, by using 
in situ hybridization techniques, it has been observed that the cells that present 
a significant expression of the kainate-type subunits GluK1, GluK2, GluK3, and 
GluK5 are distributed throughout the CNS, including nucleus striatum, hippocam-
pus, cortex, and cerebellum [16]. Likewise, there is a high expression of the GluK4 
subunit in the CA3 region of the hippocampus, as well as in the granular neurons of 
the dentate gyrus. The messenger of the GluK5 subunit, on the other hand, appears 
more abundantly and more extensively than that of the GluK4 subunit or those of 
the other subunits [15]. Because the in situ hybridization technique is informative 
and cannot reveal the subcellular distribution of a specific subunit, and because of 
pharmacological limitations, there is still much to know about the subcellular loca-
tion and physiology of these receptors.
Kainate-type glutamate receptors are well established mediators of canonical, 
ionotropic postsynaptic synaptic transmission and, presynaptically, have a modula-
tory role in regulating neurotransmitter release. In the latter regard, KARs have 
been shown to have a noncanonical metabotropic capacity, whereby they affect the 
control of both glutamate and GABA release, for review see [15, 17–22]. At some 
excitatory glutamatergic synapses, KARs’ activation can actually effect biphasic 
modulation, where low agonist concentrations facilitate glutamate release, while 
high concentrations decrease the release of the neurotransmitter, for review see 
[17, 18]. Mechanistic details of how this is achieved are subject of investigation and, 
indeed, the subcellular location of KARs responsible for presynaptic modulation 
remains contentious. Different roles of KARs in plasticity have also been described 
either in LTP or LTD, see [23] for a review of the role of KARs in plasticity.
As other glutamate receptors, KARs are directly or indirectly involved in dif-
ferent diseases, alterations of the nervous system and neurodegeneration and cell 
death processes. As previously indicated, KA is a potent neurotoxin that directly 
induces epilepsy and is used as a temporal lobe epilepsy model [5, 6]. Several lines 
of research indicate that KA directly activating KARs is involved in excitatory 
and inhibitory imbalances associated with epilepsy. The use of animal models for 
epilepsy through the use of KA injections has allowed to reproduce in great detail 
the symptoms observed in humans. The majority of studies of KARs’ involvement 
in epilepsy have studied acute KA-induced seizures [24–27]. The best demonstra-
tions of a mechanism for KARs’ involvement in acute epilepsy come from studies of 
inhibition of GABA release by the activation of presynaptic KA receptors at inter-
neuron-CA1 hippocampal synapses [24, 28, 29]. In chronic epilepsy, a role of KARs 
has been demonstrated at hippocampal mossy fibers making aberrant synapses onto 
granule cells of dentate gyrus expressing high number of KARs [30–32] reviewed 
in [6, 33]. In humans, genetic studies of members of a family affected by idiopathic 
juvenile absence epilepsy found elevated levels of Grik1 polymorphisms [34], and 
in TLE patients, GluK1 subunit containing KARs’ increased levels have also been 
found [35]. In clinical studies, NS1209 (an AMPA/KARs’ antagonist) has been 
found to decrease epileptic symptoms [36].
Different studies of neurotoxicity clearly indicate that KARs might be impor-
tant targets for neuroprotection in neurons and glial cells. The mechanism by 
which KARs produce excitotoxicity and neuronal cell death is not well understood 
mainly because of the limitations in appropriate pharmacological tools. Toxicity 
of KARs involved in multiple sclerosis has also been found onto oligodendrocytes 
and myelin related to [37, 38], and damage has also been found at axonal levels, 
where AMPA/KARs’ antagonists prevent it [39]. Interestingly, KARs have also been 
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involved in pain. They are present at dorsal roots activating nociceptors, actually 
there are clinical trials using KARs’ antagonists to try to prevent pain showing 
some levels of analgesia [36]. Additionally, KARs have been involved in ischemia 
[40, 41], migraine pain [36], Alzheimer’s disease [42], Parkinson’s disease [43, 44], 
Huntington’s Chorea [45–47], Schizophrenia [48, 49], depression [50], bipolar dis-
order [51, 52], mental retardation [53], and autism [54, 55] as reviewed in [56]. In 
general, antagonists of KARs containing particular subunits might be good targets 
to ameliorate symptoms or treat different CNS diseases and alterations.
2. KARs in the cerebellum
As indicated above, KARs are expressed in the cerebellar cortex [57–59]. As 
known, the cerebellum participates in the modulation of movement by modifying 
the activity patterns of motor neurons. Structurally, the cerebellum is composed 
of the laminar cerebellar cortex and the deep cerebellar nuclei and has five types 
of cells: Purkinje, stellate, basket, Golgi, and granule cells. Purkinje cells (PuC) are 
aligned in front of each other. Their dendritic trees form two 2-dimensional layers 
through which parallel fibers from the mossy fibers located in the granular layer 
pass. These parallel fibers (PF) establish excitatory synapses between granular cells 
and the spines of the PCs dendrites as well as the climbing fibers (CF, originating 
from the inferior olivary nucleus) with the nearby dendrites and the cellular soma. 
The parallel fibers pass orthogonally through the dendritic tree of the Purkinje 
neuron. Up to 200,000 PF form a synapse with a single PuC. Each PuC receives up to 
500 synapses of CF, all originated from a single CF. Both basket cells and stellate cells 
provide an inhibitory (GABAergic) entry to the PuC, with cells in the basket synapse 
to the initial segment of the PuC axon, and stellate cells to the dendrites [60, 61].
Presynaptic KARs participate in plasticity in the cerebellum where PF synapses 
onto PuCs mediate a form of LTD that is affected by the paired activation of CFs 
[62], Table 1; of these two types of fibers (PF and CF synapsing onto the same 
cells (PC), only PF have presynaptic KARs [62], similar to other brain regions as 
somatosensory and visual cortices in which fibers containing and noncontaining 
presynaptic ionotropic glutamate receptors synapse onto the same postsynaptic cell 
and induce LTD [63–69]. The exact role and action mechanism of KARs mediating 
LTD in the cerebellum are not well known yet and await further investigation.
The proper cerebellum development depends on a precise coordinated sequence 
of postnatal events, some of which are mediated by glutamate receptors. For 
example, NMDA receptors have been implicated in the migration of granular 
cells [70] and in the synaptic pruning of climbing fibers [71]. Although it has 
recently been shown that KARs are involved in synaptic transmission, little is 
known about their role in development. However, the expression of kainate-type 
glutamate receptor subunits in immature granule cells of the outer germinal layer 
of the developing cerebellum suggests that KARs may also have a role in neuronal 
maturation. Throughout the maturation process of the cerebellum, the quantity, 
composition, and function of KARs vary. Initially, cerebellar granular cells have a 
minimal amount of AMPARs in the postnatal period compared to KARs, which are 
predominant in immature granule cells. Different studies have shown that KARs 
composed of subunits GluK1, GluK2, and GluK5 predominate, and over the period 
of development, an increase in the number of KARs is observed and once the adult 
stage is reached, the number of KARs containing GluK1 subunits suffers a reduction 
in their expression in the granular layer, while the GluK2 and GluK5 remain con-
stant, in contrast to AMPARs that increase their number, constituting a very notable 
majority compared to KARs.
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All of these findings suggest that KARs have an important role in the develop-
ment process of the cerebellum. Some indications suggest that GluK1-containing 
KARs participate in cerebellar development in the beginning of the differentiation 
of granular cells.
Additionally, KARs have been involved in some brain alterations in the cerebellum 
and a direct relationship exists between KA injection and cerebellar ataxia. Thus, the 
cerebellum is an important target to study functions of KARs and its possible role 
causing ataxia [72–75]. Furthermore, in patients with schizophrenia, an increase in 
KARs containing GluR6 and K2 subunits is observed, which would mediate a reduc-
tion in GABAergic transmission [76, 77]. In neurodegeneration, KARs may have a role 
in calcification of the brain tissue as it has been found that local application of KA in 
some areas of the cerebellum produces changes in different ion levels, highly increas-
ing Ca2+ levels for more than 8 weeks, which mediate calcification [78] (Table 1). 
KARs have been described as producing increases in intracellular calcium [79, 80] and 
seems to signal increasing intracellular calcium without putting the cell at risk due to 
excitotoxicity, due to its low conductance in contrast to AMPARs. Due to the lack of 
knowledge on the subject, further exploration is necessary to determine the KARs’ 
role in cerebellum development and cerebellar alterations.
2.1 KARs modulating glutamate release in the cerebellum: a biphasic effect
KARs are known to be expressed in the cerebellar cortex in the axons of cer-
ebellar granule cells that form PF and make excitatory synapses with PuC [58]. 
Messenger RNA transcripts encoding for different KAR subunits and functional 
expression of KAR subtypes have been reported [81–84]. Biophysical studies with 
single-channel recording have shown GluK1 activity [85], suggesting these KARs 
are Ca2+ permeable. A biphasic action of KARs, activated by the agonist domoate, 
has been shown previously at PF-PuC synapse, with low agonist concentrations, 
facilitating synaptic transmission and higher concentrations depressing synaptic 
KARs’ activation High concentrations 
of kainate
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All of these findings suggest that KARs have an important role in the develop-
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of granular cells.
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some areas of the cerebellum produces changes in different ion levels, highly increas-
ing Ca2+ levels for more than 8 weeks, which mediate calcification [78] (Table 1). 
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seems to signal increasing intracellular calcium without putting the cell at risk due to 
excitotoxicity, due to its low conductance in contrast to AMPARs. Due to the lack of 
knowledge on the subject, further exploration is necessary to determine the KARs’ 
role in cerebellum development and cerebellar alterations.
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Messenger RNA transcripts encoding for different KAR subunits and functional 
expression of KAR subtypes have been reported [81–84]. Biophysical studies with 
single-channel recording have shown GluK1 activity [85], suggesting these KARs 
are Ca2+ permeable. A biphasic action of KARs, activated by the agonist domoate, 
has been shown previously at PF-PuC synapse, with low agonist concentrations, 
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transmission [86] in agreement with what has been found in the hippocampus 
[87–89], cortex [90], amygdala [91], and the thalamus [92]. EPSC trial-to-trial 
fluctuation analysis, failure rates, as well as paired-pulse ratios have shown that 
these facilitatory and depressive actions of KARs in the cerebellum are mediated by 
presynaptic KARs [80]. However, the precise mechanism of action by which KARs 
mediate potentiation (and depression) of synaptic transmission at PF-PuC synapses 
has remained elusive until very recently [80] (Table 1).
2.1.1  Action mechanism for KARs-mediated facilitation of glutamate release at 
cerebellar PF-PuC synapses
We have recently demonstrated that the effect of the KARs’ activation in this 
synapse requires protein kinase A (PKA) activation, since the inhibition of this 
protein by cAMP-Rp suppresses the effect of KA in glutamate release [80], in agree-
ment with previous studies in hippocampus and cortex [87–89]. This congruence 
between mechanisms at different synapses has also been seen through the inhibition 
of PKA using H-89, which eliminates KARs-mediated facilitation of glutamate 
release. Similarly, the direct activation of AC (adenylyl cyclase) using forskolin 
caused an elimination of facilitation when KARs were activated by KA (with 
NMDARs and AMPARs blocked). These data indicate that a signaling mediated by 
AC/cAMP/PKA supports the facilitation of the modulation of synaptic transmis-
sion/glutamate release in these cerebellar synapses (Figures 1–3).
As observed in other synapses, Ca2+ seems to play a fundamental role in facilitat-
ing glutamate release at PF-PuC synapses. By blocking calcium-permeable KARs 
by the selective inhibitor philanthotoxin, KAR-mediated synaptic facilitation of 
glutamate release was prevented, indicating that there is a strict requirement for 
external Ca2+ entry through KARs to support the facilitation effect observed on 
glutamate release, indicating that KARs mediating the facilitation of glutamate 
release are calcium permeable [80].
Additionally, as has been reported at hippocampal synapses, the depletion of 
intracellular Ca2+ stores by a treatment with thapsigargin (a noncompetitive cal-
cium inhibitor of the sarcoplasmic reticulum ATPase) eliminates the facilitation of 
glutamate release mediated by KARs’ activation. The same result was found when 
selectively inhibiting Ca2+-induced calcium release by using ryanodine, indicating 
that the entry of Ca2+ via KARs induces a mobilization of Ca2+ from the intratermi-
nal Ca2+ reserves to mediate the increase in glutamate release observed [80].
Furthermore, it has been observed that the facilitation of glutamate release 
mediated by the activation of KARs is sensitive to calmodulin inhibitors. Previous 
studies showed that the increase of cytosolic calcium levels activates Ca2+ depen-
dent on AC present in the terminals of parallel fibers. Through treatment with the 
calmodulin inhibitors, W-7 and calmidazolium, it has been recently shown [80] that 
the inhibition of calcium-calmodulin function prevents KAR-mediated presynaptic 
facilitation of glutamate release in cerebellar slices, supporting the hypothesis 
that after KAR activation and cytosolic elevation of Ca2+, a calmodulin-dependent 
calcium coupling activates AC, which subsequently activates the AC/cAMP/PKA 
pathway, thus promoting synaptic facilitation through an increase in neurotrans-
mitter release at PF-PuC synapses [80].
2.1.2  Action mechanism for KARs-mediated depression of glutamate release at 
cerebellar PF-PuC synapses
Recently, in the same study discussed in the previous section [80], a transient 
synaptic depression of glutamate release with high concentrations of KA (3 μM) 
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was observed as reported for other different brain areas including thalamus, cortex, 
hippocampus, and amygdala [89–92]. This depression of glutamate release was pre-
vented in the presence of cAMP-RP (which inhibits the activation of PKA), but was 
not affected by any other experimental modification discussed above with respect 
to the facilitation of glutamate release. This fact may indicate that the synaptic 
depression is probably related to an AC/cAMP/PKA signaling pathway (as for facili-
tation of glutamate release), but without the coupling of Ca2+ to the AC. Therefore, 
Figure 1. 
KAR-mediated facilitation of glutamate release involving activation of adenylyl cyclase (AC) and downstream 
protein kinase A (PKA) at PF-PuC synapses of the cerebellum. (A) Time course of KA (3 μM) effect on 
eEPSCs amplitude in the absence (circles) and presence of NBQX (squares). Insets show traces before and after 
4 min of KA perfusion in the absence (1, 2) and in the presence of 10 μM NBQX (1′, 2′). (B) Quantification of 
modulation observed in (A) and dose-response curve. (C) Time course of the effect of KA on eEPSC amplitude 
in cAMP-Rp-treated slices. (D) Inhibition of PKA by cAMP-Rp (100 μM) or H-89 (2 μM), and activation of 
AC by forskolin (30 μM) prevented the facilitatory action of KA. Inhibition of PKC with calphostin C (1 μM) 
has no effect on the KA enhancement of the eEPSC amplitude. The facilitatory effect of KA is not affected in 
slices treated with pertussis toxin. Modified from [64].
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KA receptors have alternative mechanisms for facilitating and depressing glutamate 
release at PF-Pu synapses (Figures 1–3). In previous studies, investigating mossy 
fiber-CA3 hippocampal synapses [88, 89, 93, 94], as well as the amygdala [37] and 
cortex [36], a similar mechanism has been observed additionally involving the 
activation of a G-protein for the depressive effect that may well be also the case for 
these cerebellar synapses.
Although the presynaptic function of KARs facilitating glutamate release 
implies an increase in AC/cAMP/PKA signaling induced by the calcium calmodulin 
complex, KARs appear to be negatively associated with this pathway to carry out 
synaptic transmission of depression. Previous studies at hippocampal MF-CA3 
Figure 2. 
Facilitation of glutamate release mediated by KAR activation requires an increase of Ca2+ in the cytosol and 
Ca2+ calmodulin at cerebellar PF-PuC synapses. (A) Time course of KA (3 μM) effect on eEPSCs amplitude 
in control condition (circles) and in slices treated with philanthotoxin (squares). (B) Quantification of 
modulation observed in (A). (C) Time course of KA (3 μM) effect on eEPSCs amplitude in control condition 
(circles) and in the slices treated with 25 μM W-7 (squares). (D) Quantification of modulation observed in 
(A) and in the presence of 1 μM CMZ. Modified from [64].
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synapses and thalamocortical synapses, as well as at PF-PuC synapses, have 
reported that the depression of glutamate release mediated by presynaptic KARs 
occurs through a negative coupling to the AC/cAMP/PKA pathway, being actually 
evoked by the action of a PTx-sensitive protein G [80, 88, 92]. Despite the hypoth-
eses discussed above, it is also possible that these observed mechanisms reflect 
the presence of two different types of KARs, a clear objective being to clarify this 
hypothesis in future studies.
3. Conclusions
Regarding the role and mechanisms of KARs in the modulation of glutamate 
release in the cerebellum, new and recent data indicate that the KARs effecting 
facilitation of glutamate release and synaptic transmission show a mandatory 
dependence on adenylyl cyclase (AC) and cAMP-mediated protein kinase A (PKA) 
activity. Furthermore, the KAR-mediated facilitation of transmission is contingent 
on both external Ca2+ permeation into the cytosol through KAR and repletion of 
Figure 3. 
KAR-mediated modulation of glutamate release in the cerebellum. Actions of KARs depressing or facilitating 
glutamate release at the PF-PuC synapse. KAR activation by high concentrations of KA (>3 μM) depresses 
glutamate release at PF-PuC synapses, an effect that involves Gi/o protein and the adenylate cyclase/cAMP/
protein kinase A (AC/cAMP/PKA) pathway. KAR activation by low concentrations of kainate (<0.3 μM) only 
facilitates glutamate release following activation of a Ca2+-calmodulin/AC/cAMP/PKA pathway.
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intracellular Ca2+ stores. Finally, a major sensitivity of facilitation to calmodulin 
inhibition suggests that KARs are coupled through a Ca2+-calmodulin/AC/cAMP/
PKA pathway at PF-PuC synapses in the cerebellum. KARs seem to use the inhibi-
tion of the AC/cAMP/PKA pathway to mediate a depression of glutamate release at 
the same synapses, but the activation of the AC does not involve calcium calmodu-
lin and seems to be directly activated by a PTX-sensitive G protein.
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Abstract
The synapses transmit signals between neurons in an ever-changing fashion.
Changes of synaptic transmission arise from numerous mechanisms known as syn-
aptic plasticity. The importance and complexity of the synapse has fueled research
into the molecular mechanisms underlying synaptogenesis, synaptic transmission,
and plasticity. Particularly, homeostatic plasticity refers to the local changes in
synaptic activation to generate local synaptic adaptations and network-wide
changes in activity to generate adjustments between excitation and inhibition. This
review chapter will focus on synaptic phenomena and mechanisms that are likely to
contribute to network homeostasis. In addition, it will be discussed a putative
modulation of the signaling mechanisms serving a homeostatic function as a viable
therapeutic approach for disease modification in neurological and neurodegenera-
tive disorders. To sum up, the main role of the following players in homeostatic
plasticity will be analyzed, based on what a growing body of evidence has suggested
recently: BDNF-mediated TrkB system activation; adenosine modulation system;
nitric oxide/soluble GC/cGMP signaling; astrocyte involvement—astroglial CB1
receptors; the microtubule-associated neuronal protein Tau; the signaling pathway
of the Wnt protein family; extracellular vesicles in the intercellular communication;
and estrogen involvement in non-reproductive functions.
Keywords: adenosine, astrocytes, BDNF, estrogens, extracellular vesicles,
neurodegeneration, nitric oxide, synaptic plasticity, Tau, TrkB system,
Wnt proteins
1. Introduction
The neurotransmission may be defined as the set of biochemical and
physiochemical signals which establishes neuronal communication. Changes of
synaptic transmission arise from numerous mechanisms known as synaptic plastic-
ity. Synaptic plasticity is crucial for regulating synaptic transmission or electrical
signal transduction to neuronal networks, for sharing essential information among
neurons and for maintaining homeostasis in the body.
Synaptic plasticity in the mature nervous system includes structural and
morphological modifications constituting the cellular response to the changes in
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1. Introduction
The neurotransmission may be defined as the set of biochemical and
physiochemical signals which establishes neuronal communication. Changes of
synaptic transmission arise from numerous mechanisms known as synaptic plastic-
ity. Synaptic plasticity is crucial for regulating synaptic transmission or electrical
signal transduction to neuronal networks, for sharing essential information among
neurons and for maintaining homeostasis in the body.
Synaptic plasticity in the mature nervous system includes structural and
morphological modifications constituting the cellular response to the changes in
neuronal activity that are thought to be responsible for learning and memory [1].
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The individual synaptic connections are constantly removed or recreated depending
on the neuronal environment. This plasticity is highly regulated by signals from
other cells of the nervous system, mainly the astrocytes whose function is the
maintenance of the neurons in a determined position [2]. This modeling ability is
achieved by genetic, molecular, and cellular mechanisms that influence synaptic
connections and neuronal circuits.
Various neurotransmitter receptors are functionally associated with protein
kinases and other G-proteins that modulate cascades of molecules which in turn
maintain essential cellular functions [3]. Modifications of the MAPK- and cAMP-
related signaling pathways may affect intracellular Ca2+ levels, neurotransmitter
receptors, transcription factors, and the cross-link between signaling pathways,
among other biological functions which are essential for neuroplasticity [4].
At the structural level, synaptic plasticity entails incorporation or disassociation
of α-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) receptors
from the postsynaptic membrane and the growth or constriction of the dendritic
spines where most excitatory synapses are placed [5]. At the functional level,
synaptic plasticity is considered as the long-term potentiation (LTP) or long-term
depression (LTD) of synaptic strength, with modifications in conductance through
AMPA receptors in the postsynaptic membrane. During the term of plasticity,
N-methyl-D-aspartate (NMDA) receptor activation leads to Ca2+ ions passage
through the postsynaptic membrane to trigger intracellular signaling cascades.
These events set off gene transcription, trafficking of AMPA receptor via action
dynamics, cytoskeleton reorganization, and enlargement or removal of dendritic
spines. The integrity of the synaptic structure, trafficking of AMPA receptor, and
dendritic spine dynamics are all crucial for generating lasting synaptic plasticity
modifications [5].
The AMPA receptors and NMDA receptors are the ones which synergize at
postsynaptic terminals to facilitate different forms of synaptic plasticity. Constant
activation of AMPA receptors by a series of impulses arriving at presynaptic termi-
nals leads to depolarization of the presynaptic membrane, which removes the Mg2+
ions that are obstructed at NMDA receptors [6]. Thereon, the simultaneous
excitation of pre- and postsynaptic neurons speeds up the gating of NMDA channels
and reinforces the synapse. This feature is crucial in NMDA channels for being
specifically associated with synaptic plasticity and its high permeability to Ca2+ ions.
Therefore, the second messenger Ca2+ modulates a set of signaling pathways and
the responses that collectively lead to synaptic modification [6].
Furthermore, local changes in synaptic activation to generate local synaptic
adaptations and network-wide changes in activity result in adjustments between
excitation and inhibition. These mechanisms are likely to contribute to network
homeostasis. Therefore, this review chapter will focus on synaptic phenomena
involved in homeostatic plasticity. In addition, it will be discussed a putative mod-
ulation of the signaling mechanisms serving a homeostatic function as a viable
therapeutic approach for disease modification in neurological and neurodegenera-
tive disorders.
2. BDNF-mediated TrkB system activation
Synaptic plasticity at the molecular level can be driven by increased expression
of plasticity-related genes, such as brain-derived neurotrophic factor (BDNF), cal-
cium/calmodulin kinase II (CaMKII), and cAMP response element binding (CREB)
protein, as well as by an augmented expression of both AMPA and NMDA receptors
on surface [7].
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The escalation of the synapse is a mode of homeostatic plasticity in which a
prolonged enhancement in neuronal activity leads to a compensatory decline in
excitatory transmission that is often mediated by a drop in levels of the synaptic
AMPA receptors. The blockage of sustained activity results in the opposite effect,
that is, an enhancement in excitatory transmission that is often mediated by an
augmentation in levels of the synaptic AMPA receptors [8]. The neurotrophin
BDNF and its signaling partners are the main regulators of synaptic plasticity.
BDNF may serve as a real mediator rather than simply a modulator of synaptic
plasticity and synaptic communication. As BDNF is synthesized and released in an
activity-dependent manner [9], BDNF levels could serve as signals for changes in
neuronal activity and thereby mediate synaptic scaling. BDNF and neurotransmitter
signaling cascades can work together in close temporal association to induce imme-
diate and guided effects on synaptic plasticity. What is more, specifically interfering
with BDNF-related signaling is a crucial strategy for neuronal and functionally
restorative treatments for neurological and psychiatric disorders [10].
The main functions of BDNF are mediated by its interaction with the
tropomyosin-related kinase B (TrkB) receptor [11] whose intracellular signaling
cascade activation can affect synaptic transmission and synaptic contact formation
[12]. TrkB receptors are typically localized within vesicles inside the cell and trans-
locate to the plasma membrane through neuronal activity [13]. The early effects of
BDNF are a result of the modification (e.g., protein phosphorylation) of compo-
nents that are already present at the synapse, while the long-term effects originate
from the modification of translational activity at the synapse and changes in tran-
scription. Stimulation of high-frequency inducing LTP leads to enhancement of
BDNF production [14]. Furthermore, BDNF increases neurotransmitter release and
promotes synaptic transmission and LTP [15]. Thus, it is assumable that the effects
exerted by BDNF on synaptic plasticity are TrkB mediated.
A recent study has investigated the features of neural network formation and
functions in primary hippocampal cultures in the context of chronic BDNF appli-
cation and TrkB receptor blockage [16]. It has been demonstrated that the blockage
of TrkB receptors affected the structures of synapses and even mitochondria, which
were not regarded as capable of participating in synaptic modulation for a long
period. Nevertheless, it has been shown that TrkB-mediated signaling can affect
both the ultrastructural and functional parameters of brain mitochondria, even in
normal oxygen and nutrient supply conditions. Chronic TrkB receptor blockade
leads to destructive ultrastructural changes in mitochondria, whereas the functional
activity of organelles remains intact apparently. Long-term application of BDNF
enhances the enzymatic activity of mitochondria, though this modification is not
related to changes in ultrastructure of organelles. These findings might demonstrate
that TrkB-mediated mitochondrial regulation is associated with functional changes
of the enzymatic apparatus of the respiratory chain but not with structural
reshaping of organelles. Chronic BDNF application increased the basal oxygen
consumption rate via activating respiratory chain complex II [17]. Under oxygen
stress conditions, BDNF increases the adaptive potential by impacting the func-
tional parameters of the mitochondrial apparatus. Further research should address
whether the TrkB-mediated pathway for influencing mitochondria is generalized
(i.e., carried out through nuclear genes) or directed toward an isolated organelle.
A genetically determined high level of BDNF can provide significant adaptive
potential to the nervous system, and its neuroprotective effects are induced via the
TrkB receptor system [18]. To date, it has been found that BDNF-mediated TrkB
system activation accounts for the formation of more complex functionally active
neural networks with a great level of efficiency in synaptic transmission. Thus, the
TrkB signaling system can be involved in higher cognitive functions.
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The individual synaptic connections are constantly removed or recreated depending
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other cells of the nervous system, mainly the astrocytes whose function is the
maintenance of the neurons in a determined position [2]. This modeling ability is
achieved by genetic, molecular, and cellular mechanisms that influence synaptic
connections and neuronal circuits.
Various neurotransmitter receptors are functionally associated with protein
kinases and other G-proteins that modulate cascades of molecules which in turn
maintain essential cellular functions [3]. Modifications of the MAPK- and cAMP-
related signaling pathways may affect intracellular Ca2+ levels, neurotransmitter
receptors, transcription factors, and the cross-link between signaling pathways,
among other biological functions which are essential for neuroplasticity [4].
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activation of AMPA receptors by a series of impulses arriving at presynaptic termi-
nals leads to depolarization of the presynaptic membrane, which removes the Mg2+
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ulation of the signaling mechanisms serving a homeostatic function as a viable
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on surface [7].
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The escalation of the synapse is a mode of homeostatic plasticity in which a
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Recent progress into the etiology of neurological and metabolic diseases has been
made with genome-wide association studies. BDNF/TrkB signaling contribution to
synaptic development and plasticity, neurite outgrowth, and dendritic spine for-
mation is a possible anatomical correlate of hyperconnectivity in autism-spectrum
disorder (ASD) [19] or of hypoconnectivity in monogenic obesity [20].
Growing evidence suggests that BDNF upregulation plays a key role in the
increased trophic effects in ASD. Studies on functional image have shown that, in
most young ASD patients, cortical regions appear hyperlinked, and cortical thick-
ness and brain size are enhanced [19]. These findings indicate that developing ASD
brains may occur in a modified neurotrophic environment as some ASD patients
and animal models have shown enhanced levels of BDNF.
Besides that, genome association studies now reveal different candidate obesity
genes, most of which are strongly expressed or known to act in the CNS, highlight-
ing the role of the brain in propensity to obesity. In this regard, BDNF is involved in
energy metabolism and eating behavior as partial BDNF deficiencies in mouse
models cause hyperphagia and obesity. The first case described by disruption of the
BDNF gene (11p13) in humans was that of an 8-year-old obese girl, who presented
an abnormality in chromosome 11 that altered the BDNF gene in one of the chro-
mosomal breakpoints [21]. This patient with severe hyperphagia and obesity also
presented a complex neurobehavioral phenotype, including impaired cognitive
function and memory and a distinctive hyperactive behavior.
3. Adenosine modulation system
Adenosine is a ubiquitous molecule that is directly involved in the key processes
sustaining cellular viability and adaptability, this is it, the energy charge, redox
control, DNA and RNA, and epigenetic control. The role of adenosine in the brain is
of great interest since the adenosine receptors are far more abundant in the brain
than in any other organ or cell type in mammals [22]. Though there are four plasma
membrane metabotropic receptors such as adenosine A1, A2A, A2B, and A3 recep-
tors [23], A1 and A2A receptors are the responsible ones for the effects of adenosine
in the brain. A1 receptors (A1R) are the most abundant and widely distributed,
while A2A receptors (A2AR) are more abundant in the basal ganglia and in synapses
throughout the rest of the brain. Both A1R and A2AR are mostly located in synap-
ses, particularly in glutamatergic synapses, although both receptors are also present
in other synapses [24].
Adenosine acts on A1R at a pre-synaptical level decreasing calcium influx and
glutamate release, at a post-synaptical level decreasing the activation of ionotropic
glutamate receptors and of voltage-sensitive calcium channels as well as
hyperpolarizing dendrites through a control of potassium channels. The ability of
A1R to control high-frequency-induced synaptic plasticity contrasts with that of
A2AR. Thus, A2AR are capable of enhancing the evoked release of glutamate in
different brain areas and the function of ionotropic glutamate receptors [25].
Besides, A2AR behave as fine-tuners of other neuromodulation systems, since
A2AR activation is a requirement for the synaptic effects of growth factors or
neuropeptides. What is more, A2AR activation diminishes the efficiency of pre-
synaptic inhibitory systems. Thus, A2AR commute pre-synaptic modulation from
inhibitory to facilitatory. Another significant feature of A2AR is that they have also
been found in astrocytes and microglia cells, controlling Na+/K+-ATPase, the uptake
of glutamate, the production of pro-inflammatory cytokines, and the effects
potentially contributing to the selective A2AR-mediated control of synaptic
plasticity [26].
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Different sources of extracellular adenosine activate each of these adenosine
receptors in order to control synaptic transmission by A1R and synaptic plasticity
by A2AR [27]. The predominant role of adenosine under basal conditions, in excit-
atory synapses, is an A1R-mediated inhibition of synaptic transmission. Then, an
endogenous A1R-mediated inhibitory tonus takes place under most experimental
conditions. In contrast, A2AR are only recruited upon higher frequencies of nerve
stimulation triggering plastic changes of synaptic efficiency (LTP) [28]. This selec-
tivity is consequence of the adenosine formed by synaptic ecto-nucleotidases upon
release of ATP from nerve terminals; high-frequency stimulations are needed to
trigger an excessive release of ATP [29] that significantly results in the production
of extracellular adenosine near A2AR. These A2AR then enhance the release of
glutamate and the activation of NMDA receptors, effectively reinforcing the
implementation of LTP [30].
Furthermore, the particular activation of A2AR upon higher frequencies of nerve
stimulation favors the solution of the increased feedback inhibitory synaptic mecha-
nisms with increasing frequencies of synaptic recruitment. The higher the stimula-
tion frequency, the greater the extracellular levels of adenosine and of cannabinoids
since supramaximal activation of pre-synaptic A1R or of cannabinoid CB1R can block
synaptic transmission. The neuromodulator adenosine, by operating high affinity
adenosine receptors, restrains transmission via A1 receptor (A1R) or CB1R [31].
In spite of the selective involvement of A2AR that allows simultaneously miti-
gating pre-synaptic inhibition and strengthening synaptic facilitation at the single
synapse level, A1R and A2AR actually collaborate to encode the relevance of infor-
mation at the level of brain circuits. The implementation of a potentiated transmis-
sion in a given synapse will elicit in parallel a process of hetero-synaptic depression
involving synaptic strengthening of A1R function in surrounding synapses (with
respect to this potentiated synapse). The increased recruitment of a synapse set off
the activation of the astrocytic syncytium. Within the domain covered by this
syncytium, there will be a greater astrocytic (i.e. non-synaptic) release of ATP [32],
which will be degraded by ecto-nucleotidases degrading ATP into adenosine, which
is channeled into A1R, further depressing the activity of neighboring synapses
(where A2AR are not engaged).
In conclusion, a predominant role of neuronal A2AR in the control of neuronal
damage is supported by several studies [33]. Dysfunction and damage of synapses
may be triggered by the A2AR that are located synaptically. This synapse impair-
ment is regarded as one of the earliest alterations found in different neurodegener-
ative disorders ranging from Alzheimer’s disease (AD) to depression.
Experimentally, it has been shown that blockade of A2AR prevents memory dam-
age in AD models. Therefore, the question arises whether A2AR antagonists might
have a therapeutic potential. To give some answer, a triple transgenic AD model
(3-Tg-AD) has been used with a defined onset of memory dysfunction occurring
at the age of 4 months. After the onset of memory deficits in 3-Tg-AD mice, a
treatment of 3 weeks with a selective A2AR antagonist has shown to normalize the
up-regulation of hippocampal A2AR, restore hippocampal-dependent reference
memory, and decrease hippocampal synaptic plasticity and global and
glutamatergic synaptic markers as well. These findings may point to a therapeutic-
like ability of A2AR antagonists to recover synaptic and memory dysfunction that
occur in early AD [34]. It may be assumed a role for A2AR in the early steps of
neurodegeneration, whereby the up-regulation of A2AR that occurs at the begin-
ning in synapses upon noxious brain insults [27] would set off an aberrant
overenforcement of synaptic plasticity that would interrupt synaptic function and
favor the likelihood of excitotoxic destruction of the synapse. A2AR would facilitate
synaptic plasticity under physiological conditions, while their up-regulation would
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lead to a synaptic toxicity that occurs early during the course of neuropsychiatric
illnesses. Moreover, the up-regulation and role of A2AR in the astrocyte and
microglial control suggest an involvement of A2AR in brain damage, which might
also include the control of blood flow and endothelial permeability by these recep-
tors. This entails that multiple cellular sites of action of A2AR would participate in
the ongoing process engaged in neurodegeneration [33].
4. Nitric oxide/soluble GC/cGMP signaling in synaptic plasticity
Nitric oxide (NO) plays roles in maintaining synaptic plasticity and in helping to
restore plasticity in the neuronal architecture in the CNS. NO is regarded as a
chemical transmitter which has essential functions in the mammalian central as well
as peripheral nervous system [35]. NO is the second mediator that can activate
NMDA receptors. NMDA receptor activation persistently enhances the activity of
neuronal nitric oxide synthase (nNOS) in the neuronal cytoplasm. It then catalyzes
the generation of endogenous NO from L-arginine followed by the enhanced release
of NO from neurons. Activation of these receptors by glutamate stimulates the
calcium influx into cells and the generation of NO by NOS, which rapidly stimulates
guanylate cyclase and increases cGMP synthesis [36]. Other glutamate receptors,
such as AMPA, can also produce NO; this pathway modulates the release of gluta-
mate and dopamine. Nevertheless, AMPA receptor trafficking, expression, and
S-nitrosylation activity are maintained by NO. Specifically, the N-ethylmaleimide-
sensitive factor (NSF, an ATPase) is high in neurons which binds with GluR2 and
the NSF-GluR2 interaction has shown to be important to maintain AMPA-mediated
transmission at the synapse [37]. Physiologically, synaptic NSF is S-nitrosylated by
NO from neuronal source in the mouse brain. Activation of NMDA receptors
increases the NSF-GluR2 interaction, as well as the surface insertion of GluR2.
NMDA receptors stimulate NO generation, which enhances NSF S-nitrosylation,
stimulates its association with GluR2, and increases the surface expression of
GluR2-containing AMPA receptors [38].
Additionally, NO is associated with the storage, uptake, and release of mediators,
such as acetylcholine, noradrenaline, GABA, taurine, and a glycine. NO can stimulate
its own extrasynaptic receptors, which are located some distance from sites of NO
synthesis. In addition, nNOS-containing neurons actively participate in the rostral
path of neuroblast migration, which involves new synaptic connections and influ-
ences neurogenesis [39]. Astrocyte migration is also regulated by the release of NO
under the actions of inducible nitric oxide synthase (iNOS). NO is also recognized as
critical for the formation of synapses and the growth of nerve fibers [40].
Deficits in synaptic plasticity are increasingly recognized as causes of memory
loss in AD [41]. NO is produced by NOS through NMDAR-mediated calcium input.
NO signaling comes into play in neurodegenerative diseases via the generation of
reactive nitrogen species and cGMP signaling cascades. NO also exerts
neuroprotective effects, as shown in AD mouse models, by reducing cell loss and
Tau pathology [42]. In AD models, NO has shown to be altered through various
mechanisms. For example, the NMDAR-mediated calcium entry that activates NOS
is enhanced by abnormal ryanodine receptor-(RyR-) mediated calcium-induced
calcium release. NOS and RyR protein levels are also increased in both AD mouse
models and human AD brains. In ADmice, at the presynaptic level, these conditions
increasing NO levels take place alongside excessive hippocampal synaptic depres-
sion. These deficits occur when homeostasis is placed at risk, such as in the presence
of reduced RyR-calcium release. Consequently, the hippocampal network and
cognitive function are not normal, though they appear to be so [43].
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In a study on 3-Tg-AD mice, the presynaptic terminals have shown to be the
primary site of NO regulation, with increased evoked and spontaneous vesicle
release, as determined by paired-pulse facilitation assays and spontaneous vesicle-
release properties [44]. Moreover, NO modifies the magnitude of vesicular release
by transforming spare vesicles into easily releasable vesicles [45]. In addition, NO
can increase the opening of RyR channels, possibly by means of S-nitrosylation. The
opposite interactions between augmented RyR-calcium signaling and enhanced
nNOS expression in AD neurons can sustain an increased NO production or syn-
thesis and also strengthen the presynaptic gain. At the postsynaptic level, the
neuroprotective characteristics of NO become evident by inhibiting the excessive
NMDAR-induced calcium influx and excitotoxicity via S-nitrosylation of the NR2A
subunit of the NMDA receptor. At the same time, apoptosis is decreased through
the S-nitrosylation of caspase-3, -8, and -9. The enhanced nNOS activity and NO
levels in AD brains might be neuroprotective, as proven by the selectively preserved
NOS-positive neurons in AD. Hence, continuous increases in NO exert harmful
effects, such as oxidative stress, the shredder loss of synaptic function, and
apoptosis [46].
All in all, the NO up-regulation or down-regulation may result in neuropsychi-
atric conditions, and its improvement may restore synaptic plasticity and neuronal
function. Understanding the specific molecular mechanisms maintaining these
effects can give some light as to identify ways to treat these neuropsychiatric
conditions [47]. Particularly, pathological deficits in NO signaling have been
reported in corticostriatal circuits in Huntington’s disease (HD). Studies indicate
that deficits in cortical and striatal nNOS activity and nitrergic transmission may
contribute to the progression of corticostriatal pathway dysfunction observed in
HD. In this pathology, medium-sized spiny neurons (MSNs) projecting to the
external globus pallidus appear to preferentially degenerate as a consequence of
accumulation of the abnormal huntingtin protein. What is interesting is that cortical
stimulation increases striatal NOS activity by means of a NMDA and dopamine D1
receptor-dependent mechanism. Thus, studies on nNOS knockout mice have
proven that striatal MSNs are significantly less sensitive to cortical drive when
compared with wild-type controls, indicating that NO signaling plays a critical role
in maintaining corticostriatal transmission [48]. Therefore, deficiencies in nNOS
activity and NO signaling reported in HD could be associated with decreased excit-
atory corticostriatal transmission and motor dysfunction. From this concluding
remark, it is likely that HD patients might benefit from pharmacotherapies aimed to
favor nitrergic signaling and corticostriatal transmission.
Conversely, the protective effect of NMDA antagonists in conditions of in vivo
cerebral ischemia supports that influx of Ca2+ through NMDA-receptor channels
constitute the main driver of glutamate neurotoxicity, a mechanism being of path-
ological importance. Studies on the role of NO in NMDA-mediated
neurodegeneration have given some light with the use of mice lacking individual
NOSs subjected to ischemia. For instance, it has been found that nNOS contributed
to the early damage, whereas endothelial NOS (eNOS) was protective, reflecting its
relevance in cerebral blood flow and, likely, in inhibiting both leucocyte adhesion to
the endothelium and platelet aggregation [49]. Reduced synthesis and availability of
eNO may contribute to the development of dementia by favoring the onset and
progression of atherosclerosis, vasoconstriction, and impaired cerebral blood flow
regulation. Furthermore, the inducible isoform of NOS (iNOS) that starts to be
expressed in the following days to an ischemic event appeared to provide additional
damage. iNOS is expressed in macrophages and glial cells in response to pro-
inflammatory cytokines or endotoxin. In the brain, widespread expression of iNOS
is pathologic and has been observed in neurological diseases, such as multiple
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NMDA receptors stimulate NO generation, which enhances NSF S-nitrosylation,
stimulates its association with GluR2, and increases the surface expression of
GluR2-containing AMPA receptors [38].
Additionally, NO is associated with the storage, uptake, and release of mediators,
such as acetylcholine, noradrenaline, GABA, taurine, and a glycine. NO can stimulate
its own extrasynaptic receptors, which are located some distance from sites of NO
synthesis. In addition, nNOS-containing neurons actively participate in the rostral
path of neuroblast migration, which involves new synaptic connections and influ-
ences neurogenesis [39]. Astrocyte migration is also regulated by the release of NO
under the actions of inducible nitric oxide synthase (iNOS). NO is also recognized as
critical for the formation of synapses and the growth of nerve fibers [40].
Deficits in synaptic plasticity are increasingly recognized as causes of memory
loss in AD [41]. NO is produced by NOS through NMDAR-mediated calcium input.
NO signaling comes into play in neurodegenerative diseases via the generation of
reactive nitrogen species and cGMP signaling cascades. NO also exerts
neuroprotective effects, as shown in AD mouse models, by reducing cell loss and
Tau pathology [42]. In AD models, NO has shown to be altered through various
mechanisms. For example, the NMDAR-mediated calcium entry that activates NOS
is enhanced by abnormal ryanodine receptor-(RyR-) mediated calcium-induced
calcium release. NOS and RyR protein levels are also increased in both AD mouse
models and human AD brains. In ADmice, at the presynaptic level, these conditions
increasing NO levels take place alongside excessive hippocampal synaptic depres-
sion. These deficits occur when homeostasis is placed at risk, such as in the presence
of reduced RyR-calcium release. Consequently, the hippocampal network and
cognitive function are not normal, though they appear to be so [43].
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In a study on 3-Tg-AD mice, the presynaptic terminals have shown to be the
primary site of NO regulation, with increased evoked and spontaneous vesicle
release, as determined by paired-pulse facilitation assays and spontaneous vesicle-
release properties [44]. Moreover, NO modifies the magnitude of vesicular release
by transforming spare vesicles into easily releasable vesicles [45]. In addition, NO
can increase the opening of RyR channels, possibly by means of S-nitrosylation. The
opposite interactions between augmented RyR-calcium signaling and enhanced
nNOS expression in AD neurons can sustain an increased NO production or syn-
thesis and also strengthen the presynaptic gain. At the postsynaptic level, the
neuroprotective characteristics of NO become evident by inhibiting the excessive
NMDAR-induced calcium influx and excitotoxicity via S-nitrosylation of the NR2A
subunit of the NMDA receptor. At the same time, apoptosis is decreased through
the S-nitrosylation of caspase-3, -8, and -9. The enhanced nNOS activity and NO
levels in AD brains might be neuroprotective, as proven by the selectively preserved
NOS-positive neurons in AD. Hence, continuous increases in NO exert harmful
effects, such as oxidative stress, the shredder loss of synaptic function, and
apoptosis [46].
All in all, the NO up-regulation or down-regulation may result in neuropsychi-
atric conditions, and its improvement may restore synaptic plasticity and neuronal
function. Understanding the specific molecular mechanisms maintaining these
effects can give some light as to identify ways to treat these neuropsychiatric
conditions [47]. Particularly, pathological deficits in NO signaling have been
reported in corticostriatal circuits in Huntington’s disease (HD). Studies indicate
that deficits in cortical and striatal nNOS activity and nitrergic transmission may
contribute to the progression of corticostriatal pathway dysfunction observed in
HD. In this pathology, medium-sized spiny neurons (MSNs) projecting to the
external globus pallidus appear to preferentially degenerate as a consequence of
accumulation of the abnormal huntingtin protein. What is interesting is that cortical
stimulation increases striatal NOS activity by means of a NMDA and dopamine D1
receptor-dependent mechanism. Thus, studies on nNOS knockout mice have
proven that striatal MSNs are significantly less sensitive to cortical drive when
compared with wild-type controls, indicating that NO signaling plays a critical role
in maintaining corticostriatal transmission [48]. Therefore, deficiencies in nNOS
activity and NO signaling reported in HD could be associated with decreased excit-
atory corticostriatal transmission and motor dysfunction. From this concluding
remark, it is likely that HD patients might benefit from pharmacotherapies aimed to
favor nitrergic signaling and corticostriatal transmission.
Conversely, the protective effect of NMDA antagonists in conditions of in vivo
cerebral ischemia supports that influx of Ca2+ through NMDA-receptor channels
constitute the main driver of glutamate neurotoxicity, a mechanism being of path-
ological importance. Studies on the role of NO in NMDA-mediated
neurodegeneration have given some light with the use of mice lacking individual
NOSs subjected to ischemia. For instance, it has been found that nNOS contributed
to the early damage, whereas endothelial NOS (eNOS) was protective, reflecting its
relevance in cerebral blood flow and, likely, in inhibiting both leucocyte adhesion to
the endothelium and platelet aggregation [49]. Reduced synthesis and availability of
eNO may contribute to the development of dementia by favoring the onset and
progression of atherosclerosis, vasoconstriction, and impaired cerebral blood flow
regulation. Furthermore, the inducible isoform of NOS (iNOS) that starts to be
expressed in the following days to an ischemic event appeared to provide additional
damage. iNOS is expressed in macrophages and glial cells in response to pro-
inflammatory cytokines or endotoxin. In the brain, widespread expression of iNOS
is pathologic and has been observed in neurological diseases, such as multiple
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sclerosis, stroke, and AD. Increased NO production and iNOS expression have been
observed after experimental and clinical traumatic brain injury (TBI). iNOS knock-
out mice showed reduction in infarct volume and motor deficits after focal ischemia
compared with wild-type mice. In an exploratory phase II study trial, TBI patients
treated with the most selective inhibitor of human iNOS reported to date showed
significant improvement in clinical outcome [50]. These studies suggested a
neuroprotective effect of iNOS inhibition after TBI.
5. Astrocyte involvement—astroglial CB1 receptors
Astrocytes are the most abundant glial cell population in the brain [51]. One of
the most intriguing features of astrocytes is the control of synaptic plasticity and
memory functions. Astrocytes contribute in shaping different types of synaptic
plasticity that challenges the generation of experimental models enabling the dis-
tinction between the neuronal contribution and the astroglial contribution in the
control of a given function [52].
The finding of a large number of astrocytes and increased expression of the α7
nAChRs subunit on these cells in hippocampus and temporal cortex of sporadic AD
patients have suggested an involvement of the astrocytic α7 nAChRs in the metab-
olism of Aβ and a relationship with the amyloid cascade [53]. It has been proven
that Aβ, at physiological levels, controls synaptic activity and acts as a positive or
negative regulator post-synaptically. In fact, Aβ either activates or inhibits α7
nAChRs in a dose-dependent manner. In the healthy brain, Aβ enhances spontane-
ous astrocyte calcium transients, regulating neuron-glia signaling in a nAChR-
dependent manner [54]. On the other hand, Aβ accumulation increases astrocytic
α7 nAChRs expression and subsequently increases intracellular calcium released
from intracellular stores contributing to a number of inflammatory cascades.
The nAChRs from astrocytes can be activated by the transmitters released from
presynaptic terminals or neurotransmitters located in the interstitial space [52]. For
instance, the nAChRs agonist acetylcholine elevates intracellular calcium in astro-
cytes, stimulating the release of glutamate gliotransmitter and consequently the
NMDA receptor-dependent currents in neurons. It results in an increase of the
efficient synaptic transmission and strength. This mechanism explains the Aβ-
induced hippocampal LTP. Then, Aβ-α7 nAChRs interaction increases astrocytic
activity to induce glutamate gliotransmission which contributes to synaptic plastic-
ity and cognition [55]. However, pathological concentrations of Aβ, as occurred in
AD, induces LTD as Aβ oligomers-induced glutamate release from astrocytes causes
excitotoxic damage and synaptic loss in neurons. In essence, pathological levels of
Aβ cause α7 nAChR-induced gliotransmission dysregulation leading to increased
excitability within the hippocampal neural network [56]. What is more, endoge-
nous stimulation of α7 nAChRs on astrocytes causes expression of further AMPA
receptors post-synaptically at glutamatergic synapses of neurons. Consequently, the
ratio of AMPA-evoked synaptic currents increases.
There is evidence that GABA is abundantly produced and released by activated
astrocytes. A non-physiological increase in tonic GABA release from reactive astro-
cytes in the hippocampus may be directly responsible for the memory impairment
in AD. It has been shown that alterations of kynurenic acid, an astrocyte-derived
antagonist of the α7 nAChRs, are associated with the impairment of the cognitive
function in AD patients. In fact, kynurenic acid at low concentrations inhibits
GABAergic neurotransmission triggered by α7 nAChRs activation [57]. Therefore,
prevention of GABAergic neurotransmission by α7 nAChRs inhibition through
kynurenic acid may protect against AD.
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The α7-specific agonists decrease IL-6 production in cell lines derived from astro-
cytes. Conversely, internalization of these receptors in astrocytes by binding to α7-
specific antibodies could stimulate IL-6 production. The α7 nAChRs internalization
might provoke neuroinflammation within the brain by inducing IL-6 production in
astrocytes. Furthermore, evidence shows that treatment with different α7 nAChRs
agonists prevent neuroinflammation in AD-affected brains and suppress elevated
levels of astrocyte-related pro-inflammatory cytokines, such as TNF-α [58].
Microglia play different roles in the healthy brain which include neuronal syn-
apse monitoring, phagocytosis of neuronal debris, and cell migration as well as
proliferation. Microglia show a typical resting phenotype in the healthy CNS,
becoming activated in response to excessive neuronal activity during neurochemical
or electrically stimulations. It has been shown that increased activation of astrocytic
α4β2 and α7 nAChRs drives the expression of glial cell-derived neurotrophic factor
(GDNF) [59]. Astrocyte-derived GDNF binds to GDNF family receptor alpha1
(GFRα1) and activates intracellular signaling pathways that lead to inhibition of
microglial activation and protection of neurons from neurodegeneration [60].
The astroglial type-1-cannabinoid (CB1) receptor signaling recently emerged as
the mediator of several forms of synaptic plasticity associated to important cogni-
tive functions [61]. The presence of CB1 and type-2 (CB2) receptors in astrocytes
was first described in human and rodent primary cultures. Particularly, CB1 recep-
tors are mainly located at presynaptic terminals of different types of neurons,
inhibiting neurotransmitter release. Although the signaling of CB1 receptors in
astrocytes has been partially investigated, it has been suggested that they are able to
couple to different intracellular signaling pathways in this type of cells, therefore
providing high adaptability to endocannabinoid-mediated responses in these cells.
The first endocannabinoid identified was arachidonoyl-ethanolamide, known as
anandamide [62]. Arachidonoyl-ethanolamide mimics the cannabinoid “tetrad”
effects (i.e., hypolocomotion, antinociception, catalepsy, and hypothermia) in
rodents. The second discovered endocannabinoid, 2-arachidonoyl-glycerol (2-AG)
is considered as the main effector of most of the CB1 receptor-mediated endoge-
nous regulation of synaptic transmission. Endocannabinoids’ precursors are located
in cell membranes and their transformation into actual endocannabinoids is thought
to mainly occur in an activity-dependent manner. Endocannabinoids are likely
produced, mobilized, and degraded by astrocytes in vivo, suggesting the presence of
an astroglial autocrine and/or paracrine endocannabinoid signaling.
Astrocytic processes express transporters GLT-1 and GLAST for glutamate, par-
ticipating in the rapid removal of glutamate released into the synaptic cleft, which is
essential for both the termination of synaptic transmission and maintenance of
physiological neuronal excitability. Since increased stimulation of glutamate recep-
tors is highly toxic for neurons, glutamate uptake by astrocytes is crucial for
protecting neurons against excitotoxicity. In this regard, it has been observed that
pharmacological blockade of CB1 receptors reduces epileptiform discharges of hip-
pocampal slices through a direct control on astrocytic calcium signaling, suggesting
that over-activation of astroglial CB1 receptors might promote the maintenance of
brain excitotoxicity [61].
Intriguingly, whereas CB1 receptors on glutamatergic neurons have been found to
reduce glutamate release and excitoxicity, astroglial CB1 receptors have been shown
to promote astroglial-dependent activation of glutamatergic transmission [63]. These
potentially opposite effects at neurons or astroglial cells might indicate the complex-
ity in the regulation of excitatory output by the endocannabinoid system.
However, arachidonoyl-ethanolamide has shown to reverse AMPA-induced
neurotoxicity and down-regulation of GLT-1 and GLAST (glutamate transporters)
mRNA in cultures of mouse astrocyte and in the spinal cord of a mouse model of
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sclerosis, stroke, and AD. Increased NO production and iNOS expression have been
observed after experimental and clinical traumatic brain injury (TBI). iNOS knock-
out mice showed reduction in infarct volume and motor deficits after focal ischemia
compared with wild-type mice. In an exploratory phase II study trial, TBI patients
treated with the most selective inhibitor of human iNOS reported to date showed
significant improvement in clinical outcome [50]. These studies suggested a
neuroprotective effect of iNOS inhibition after TBI.
5. Astrocyte involvement—astroglial CB1 receptors
Astrocytes are the most abundant glial cell population in the brain [51]. One of
the most intriguing features of astrocytes is the control of synaptic plasticity and
memory functions. Astrocytes contribute in shaping different types of synaptic
plasticity that challenges the generation of experimental models enabling the dis-
tinction between the neuronal contribution and the astroglial contribution in the
control of a given function [52].
The finding of a large number of astrocytes and increased expression of the α7
nAChRs subunit on these cells in hippocampus and temporal cortex of sporadic AD
patients have suggested an involvement of the astrocytic α7 nAChRs in the metab-
olism of Aβ and a relationship with the amyloid cascade [53]. It has been proven
that Aβ, at physiological levels, controls synaptic activity and acts as a positive or
negative regulator post-synaptically. In fact, Aβ either activates or inhibits α7
nAChRs in a dose-dependent manner. In the healthy brain, Aβ enhances spontane-
ous astrocyte calcium transients, regulating neuron-glia signaling in a nAChR-
dependent manner [54]. On the other hand, Aβ accumulation increases astrocytic
α7 nAChRs expression and subsequently increases intracellular calcium released
from intracellular stores contributing to a number of inflammatory cascades.
The nAChRs from astrocytes can be activated by the transmitters released from
presynaptic terminals or neurotransmitters located in the interstitial space [52]. For
instance, the nAChRs agonist acetylcholine elevates intracellular calcium in astro-
cytes, stimulating the release of glutamate gliotransmitter and consequently the
NMDA receptor-dependent currents in neurons. It results in an increase of the
efficient synaptic transmission and strength. This mechanism explains the Aβ-
induced hippocampal LTP. Then, Aβ-α7 nAChRs interaction increases astrocytic
activity to induce glutamate gliotransmission which contributes to synaptic plastic-
ity and cognition [55]. However, pathological concentrations of Aβ, as occurred in
AD, induces LTD as Aβ oligomers-induced glutamate release from astrocytes causes
excitotoxic damage and synaptic loss in neurons. In essence, pathological levels of
Aβ cause α7 nAChR-induced gliotransmission dysregulation leading to increased
excitability within the hippocampal neural network [56]. What is more, endoge-
nous stimulation of α7 nAChRs on astrocytes causes expression of further AMPA
receptors post-synaptically at glutamatergic synapses of neurons. Consequently, the
ratio of AMPA-evoked synaptic currents increases.
There is evidence that GABA is abundantly produced and released by activated
astrocytes. A non-physiological increase in tonic GABA release from reactive astro-
cytes in the hippocampus may be directly responsible for the memory impairment
in AD. It has been shown that alterations of kynurenic acid, an astrocyte-derived
antagonist of the α7 nAChRs, are associated with the impairment of the cognitive
function in AD patients. In fact, kynurenic acid at low concentrations inhibits
GABAergic neurotransmission triggered by α7 nAChRs activation [57]. Therefore,
prevention of GABAergic neurotransmission by α7 nAChRs inhibition through
kynurenic acid may protect against AD.
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The α7-specific agonists decrease IL-6 production in cell lines derived from astro-
cytes. Conversely, internalization of these receptors in astrocytes by binding to α7-
specific antibodies could stimulate IL-6 production. The α7 nAChRs internalization
might provoke neuroinflammation within the brain by inducing IL-6 production in
astrocytes. Furthermore, evidence shows that treatment with different α7 nAChRs
agonists prevent neuroinflammation in AD-affected brains and suppress elevated
levels of astrocyte-related pro-inflammatory cytokines, such as TNF-α [58].
Microglia play different roles in the healthy brain which include neuronal syn-
apse monitoring, phagocytosis of neuronal debris, and cell migration as well as
proliferation. Microglia show a typical resting phenotype in the healthy CNS,
becoming activated in response to excessive neuronal activity during neurochemical
or electrically stimulations. It has been shown that increased activation of astrocytic
α4β2 and α7 nAChRs drives the expression of glial cell-derived neurotrophic factor
(GDNF) [59]. Astrocyte-derived GDNF binds to GDNF family receptor alpha1
(GFRα1) and activates intracellular signaling pathways that lead to inhibition of
microglial activation and protection of neurons from neurodegeneration [60].
The astroglial type-1-cannabinoid (CB1) receptor signaling recently emerged as
the mediator of several forms of synaptic plasticity associated to important cogni-
tive functions [61]. The presence of CB1 and type-2 (CB2) receptors in astrocytes
was first described in human and rodent primary cultures. Particularly, CB1 recep-
tors are mainly located at presynaptic terminals of different types of neurons,
inhibiting neurotransmitter release. Although the signaling of CB1 receptors in
astrocytes has been partially investigated, it has been suggested that they are able to
couple to different intracellular signaling pathways in this type of cells, therefore
providing high adaptability to endocannabinoid-mediated responses in these cells.
The first endocannabinoid identified was arachidonoyl-ethanolamide, known as
anandamide [62]. Arachidonoyl-ethanolamide mimics the cannabinoid “tetrad”
effects (i.e., hypolocomotion, antinociception, catalepsy, and hypothermia) in
rodents. The second discovered endocannabinoid, 2-arachidonoyl-glycerol (2-AG)
is considered as the main effector of most of the CB1 receptor-mediated endoge-
nous regulation of synaptic transmission. Endocannabinoids’ precursors are located
in cell membranes and their transformation into actual endocannabinoids is thought
to mainly occur in an activity-dependent manner. Endocannabinoids are likely
produced, mobilized, and degraded by astrocytes in vivo, suggesting the presence of
an astroglial autocrine and/or paracrine endocannabinoid signaling.
Astrocytic processes express transporters GLT-1 and GLAST for glutamate, par-
ticipating in the rapid removal of glutamate released into the synaptic cleft, which is
essential for both the termination of synaptic transmission and maintenance of
physiological neuronal excitability. Since increased stimulation of glutamate recep-
tors is highly toxic for neurons, glutamate uptake by astrocytes is crucial for
protecting neurons against excitotoxicity. In this regard, it has been observed that
pharmacological blockade of CB1 receptors reduces epileptiform discharges of hip-
pocampal slices through a direct control on astrocytic calcium signaling, suggesting
that over-activation of astroglial CB1 receptors might promote the maintenance of
brain excitotoxicity [61].
Intriguingly, whereas CB1 receptors on glutamatergic neurons have been found to
reduce glutamate release and excitoxicity, astroglial CB1 receptors have been shown
to promote astroglial-dependent activation of glutamatergic transmission [63]. These
potentially opposite effects at neurons or astroglial cells might indicate the complex-
ity in the regulation of excitatory output by the endocannabinoid system.
However, arachidonoyl-ethanolamide has shown to reverse AMPA-induced
neurotoxicity and down-regulation of GLT-1 and GLAST (glutamate transporters)
mRNA in cultures of mouse astrocyte and in the spinal cord of a mouse model of
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multiple sclerosis via CB1 receptor [64]. Thus, the role of astroglial CB1 receptors in
the regulation of excitatory amino acids in the context of excitotoxic processes
might depend on the conditions of the brain circuits involved and the specific
activation of the endocannabinoid system at different sites. It might be hypothe-
sized that astroglial CB1 receptors might exert a bidirectional control of excitatory
transmission and excitotoxicity [61].
The role of astroglial CB1 receptors in the modulation of excitatory transmission
in the hippocampus was first reported by Navarrete and Araque [65]. They found
that hippocampal astrocytes express functional CB1 receptors that increase intra-
cellular Ca2+ levels in astrocytes following electrical stimulation of adjacent neurons.
CB1 receptor-dependent increase of intracellular Ca2+ levels in astrocytes requires
activation of PLC, suggesting that the interaction of CB1 receptors with the Gαq
protein subunit may be favored in astrocytes as compared to neurons. Astroglial
CB1 receptors activation is necessary for NMDA receptor-mediated neuronal excit-
ability evoked by astrocyte Ca2+ elevations, suggesting their importance for
astrocyte-neuron excitatory signaling. However, these results do not characterize
neither the endogenous NMDA receptor agonist implicated in this process nor the
cellular origin and identity of the released eCBs that act at astroglial CB1 receptors
in these conditions. Astroglial CB1 receptors mediate heterosynaptic potentiation at
excitatory CA3-CA1 synapses in a Group I mGluR-dependent fashion. Importantly,
this phenomenon coexists with depolarization-induced suppression of excitation
(DSE, short-term inhibition of excitatory transmission) mediated by neuronal CB1
receptors at homosynaptic connections [66].
Finally, astroglial CB1 receptors mediate spike timing-dependent LTD (tLTD) in
the neocortex. tLTD is induced by paired stimulations of the pre- and postsynaptic
elements, leading to a reduction of presynaptic release of glutamate. CB1 receptor-
dependent tLTD has been also described at cortico-striatal synapses and may imply
astroglial CB1 signaling as well. This form of synaptic plasticity has been associated
to the neuronal coding of sensory experiences in vivo. Interestingly, one of the major
consequences of exogenous cannabinoids administration, including THC, is an
alteration of perception, but little is known about the mechanisms underlying these
effects [67]. Therefore, it is possible that the overstimulation of CB1 receptors
impairs sensory functions by a deregulation of tLTD.
6. The microtubule-associated neuronal protein Tau
The neuronal cytoskeleton is the major intracellular structure that determines
the morphology of neurons and plays a critical role in the development of the
nervous system, neuronal plasticity, and neurodegenerative diseases [68]. In par-
ticular, changes in microtubule (MT) dynamics are involved not only in axon
formation and axonal sprouting but also in mediating structural and functional
changes of dendritic spines, which represent the major site of excitatory postsyn-
aptic input [69].
MT dynamics are regulated by several factors affecting the assembly state of this
polymer. MT-associated proteins (MAPs) promote MT nucleation and elongation in
a compartment-specific manner and are also subject to regulation by posttransla-
tional modification [69]. Tau is of particular importance since it becomes enriched
in the axonal compartment during neuronal development and redistributes to the
somato-dendritic compartment in a state of hyperphosphorylation during neurode-
generative pathologies such as AD and other tauopathies [70]. Strikingly, acute or
chronic knockdown of Tau does not appear to affect MT stability and organization
or the overall structure of a neuron to a major extent. This feature raises the
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question whether Tau possesses activities beyond its direct role in regulating axonal
MT polymerization, which is altered in AD and other tauopathies. In this regard,
Tau is an intrinsically disordered protein, which interacts with different partners.
Tau stands out for its structural plasticity allowing it to react quickly in response to
changes in their environment by posttranslational modifications [71]. Then, Tau
may affect various signaling and regulatory processes dependent on its modifica-
tion, thereby regulating the function and plasticity of neurons during learning,
memory, and degenerative processes.
In order to make a functional assessment of Tau role with regard to neuronal
activity and network properties, several electrophysiological studies have been
performed using Tau knock-out (KO) mice or Tau knockdown experiments. Com-
plete absence of Tau or a decrease in the amount of Tau on neuronal activity has
been studied by recordings from individual cortical neurons as well as from intact
neuronal circuits in acutely isolated tissue slices. The focus in most studies was
placed on the influence of Tau on LTP or LTD generation in the hippocampus both
being established experimental paradigms of synaptic plasticity underlying learning
and memory formation. Cantero et al. [72] has studied the involvement of Tau in
shaping electrophysiological properties of neural oscillations in different neocortical
regions and hippocampus during spontaneous exploratory motor behavior of
4 month old mice. They observed a significant slowdown of the hippocampal theta
rhythm, which is known to play a crucial role in learning and memory function.
Furthermore, they found decreased levels of gamma long-range synchronization in
the KO animals, while power and peak frequency in the gamma band oscillations
(30–80 Hz) recorded from neocortex and hippocampus remained unchanged. As a
result, it was hypothesized that the lack of physiologically phosphorylated Tau
during early stages of development may influence the maturation of parvalbumin-
containing interneurons affecting the spatiotemporal structure of long-range
gamma synchronization between hippocampus and neocortex.
It was recently demonstrated that Tau exerts an important mediatory role in
regulating the interaction between protein kinase C binding protein 1 and GluA2, a
molecular mechanism fundamental to AMPA receptor internalization [73]. Bio-
chemical and electrophysiological assays have allowed to show that specific phos-
phorylation at S396 of Tau is related to and required for LTD. In addition, the
absence of Tau led to the reversion of deficiencies in spatial memory, pointing out a
relevant role of Tau in hippocampal LTD. Thus, Tau seems to be decisively involved
in the maintenance of physiological synaptic transmission and synaptic plasticity.
For many years, in terms of location, Tau has been considered to be an exclu-
sively intracellular protein. However, Tau can be released from neurons and it has
been found in the cerebrospinal fluid of AD patients. This feature may affect
network functions by directly influencing the activity of multiple neurons. Stimu-
lation of neuronal activity can induce Tau release from healthy cortical neurons,
suggesting that Tau secretion is a physiological process [74]. In vivo microdialysis
has proven that increasing neuronal activity raises the level of extracellular Tau. The
elimination rate of Tau from the extracellular space in the brain is slow suggesting
that Tau can be present for long times outside of neurons and influence other cells.
Extracellular Tau has a reduced phosphorylation state and is enriched in C-
terminally truncated forms. Besides, it has been demonstrated that a Tau fragment
resulting from the cleavage through the effector caspase-3 exhibits enhanced secre-
tion [75]. It is not yet clear in which form Tau is present in the extracellular space
and how it potentially influences other neurons. Extracellular Tau might affect
network functions by acting on other cells through receptor-mediated mechanisms.
Alternatively, extracellular Tau might be taken up by other neurons and modulate
their signaling cascades. Several studies have reported uptake of Tau aggregates and
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multiple sclerosis via CB1 receptor [64]. Thus, the role of astroglial CB1 receptors in
the regulation of excitatory amino acids in the context of excitotoxic processes
might depend on the conditions of the brain circuits involved and the specific
activation of the endocannabinoid system at different sites. It might be hypothe-
sized that astroglial CB1 receptors might exert a bidirectional control of excitatory
transmission and excitotoxicity [61].
The role of astroglial CB1 receptors in the modulation of excitatory transmission
in the hippocampus was first reported by Navarrete and Araque [65]. They found
that hippocampal astrocytes express functional CB1 receptors that increase intra-
cellular Ca2+ levels in astrocytes following electrical stimulation of adjacent neurons.
CB1 receptor-dependent increase of intracellular Ca2+ levels in astrocytes requires
activation of PLC, suggesting that the interaction of CB1 receptors with the Gαq
protein subunit may be favored in astrocytes as compared to neurons. Astroglial
CB1 receptors activation is necessary for NMDA receptor-mediated neuronal excit-
ability evoked by astrocyte Ca2+ elevations, suggesting their importance for
astrocyte-neuron excitatory signaling. However, these results do not characterize
neither the endogenous NMDA receptor agonist implicated in this process nor the
cellular origin and identity of the released eCBs that act at astroglial CB1 receptors
in these conditions. Astroglial CB1 receptors mediate heterosynaptic potentiation at
excitatory CA3-CA1 synapses in a Group I mGluR-dependent fashion. Importantly,
this phenomenon coexists with depolarization-induced suppression of excitation
(DSE, short-term inhibition of excitatory transmission) mediated by neuronal CB1
receptors at homosynaptic connections [66].
Finally, astroglial CB1 receptors mediate spike timing-dependent LTD (tLTD) in
the neocortex. tLTD is induced by paired stimulations of the pre- and postsynaptic
elements, leading to a reduction of presynaptic release of glutamate. CB1 receptor-
dependent tLTD has been also described at cortico-striatal synapses and may imply
astroglial CB1 signaling as well. This form of synaptic plasticity has been associated
to the neuronal coding of sensory experiences in vivo. Interestingly, one of the major
consequences of exogenous cannabinoids administration, including THC, is an
alteration of perception, but little is known about the mechanisms underlying these
effects [67]. Therefore, it is possible that the overstimulation of CB1 receptors
impairs sensory functions by a deregulation of tLTD.
6. The microtubule-associated neuronal protein Tau
The neuronal cytoskeleton is the major intracellular structure that determines
the morphology of neurons and plays a critical role in the development of the
nervous system, neuronal plasticity, and neurodegenerative diseases [68]. In par-
ticular, changes in microtubule (MT) dynamics are involved not only in axon
formation and axonal sprouting but also in mediating structural and functional
changes of dendritic spines, which represent the major site of excitatory postsyn-
aptic input [69].
MT dynamics are regulated by several factors affecting the assembly state of this
polymer. MT-associated proteins (MAPs) promote MT nucleation and elongation in
a compartment-specific manner and are also subject to regulation by posttransla-
tional modification [69]. Tau is of particular importance since it becomes enriched
in the axonal compartment during neuronal development and redistributes to the
somato-dendritic compartment in a state of hyperphosphorylation during neurode-
generative pathologies such as AD and other tauopathies [70]. Strikingly, acute or
chronic knockdown of Tau does not appear to affect MT stability and organization
or the overall structure of a neuron to a major extent. This feature raises the
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question whether Tau possesses activities beyond its direct role in regulating axonal
MT polymerization, which is altered in AD and other tauopathies. In this regard,
Tau is an intrinsically disordered protein, which interacts with different partners.
Tau stands out for its structural plasticity allowing it to react quickly in response to
changes in their environment by posttranslational modifications [71]. Then, Tau
may affect various signaling and regulatory processes dependent on its modifica-
tion, thereby regulating the function and plasticity of neurons during learning,
memory, and degenerative processes.
In order to make a functional assessment of Tau role with regard to neuronal
activity and network properties, several electrophysiological studies have been
performed using Tau knock-out (KO) mice or Tau knockdown experiments. Com-
plete absence of Tau or a decrease in the amount of Tau on neuronal activity has
been studied by recordings from individual cortical neurons as well as from intact
neuronal circuits in acutely isolated tissue slices. The focus in most studies was
placed on the influence of Tau on LTP or LTD generation in the hippocampus both
being established experimental paradigms of synaptic plasticity underlying learning
and memory formation. Cantero et al. [72] has studied the involvement of Tau in
shaping electrophysiological properties of neural oscillations in different neocortical
regions and hippocampus during spontaneous exploratory motor behavior of
4 month old mice. They observed a significant slowdown of the hippocampal theta
rhythm, which is known to play a crucial role in learning and memory function.
Furthermore, they found decreased levels of gamma long-range synchronization in
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oligomers, which may cause network damage by propagation of protein abnormal-
ities. For instance, it has been suggested a prion-like spreading of a pathogenic
misfolded Tau in a deterministic manner to distinct brain regions [76]. However, it
is not clear whether or not extracellular soluble Tau is internalized by neurons at
physiological conditions. Application of exogenous Tau from cerebral cortex of AD
brain evoked a strong LTP inhibition at CA3-CA1 synapses in hippocampal brain
slices being elicited by theta burst stimulation. Moreover, a short exposure to
oligomers, but not monomers, of extracellular recombinant human Tau causes a
concentration-dependent impairment of LTP in the CA3-CA1 pathway and mem-
ory formation [77]. These effects were reproduced both by Tau oligomers from AD
human specimens, as well as those produced in mice overexpressing the human
Tau. In vitro conditions has evidenced that oligomerized Tau passes the cell mem-
brane and is internalized by neurons. However, it is unclear whether extracellular
Tau acts in these experiments through receptor-mediated mechanisms or after
internalization.
With all of it, it appears clear that Tau exerts systemic effects and modulates
network functions both in the CNS and the peripheral nervous system. Conse-
quently, changes in the Tau level will produce various side effects. Though most
available data are still controversial at length, general trends begin to become
apparent from several experimental approaches. The course of motor impairments
as a consequence of reduced Tau levels at advanced age might be caused by an
impact on the peripheral motor system. Mild cognitive and memory deficits and a
disruption of physiological synaptic transmission and synaptic plasticity have been
repeatedly reported. Even posttranslational modifications of Tau possessing patho-
logic effect may serve protective functions for synapses, which would be impaired
in circumstances of Tau depletion. Experiments with hibernating animals have
rendered evidence for a protective function of Tau phosphorylation, providing a
striking model for extreme plasticity, as numerous synaptic contacts are lost during
hibernation and regenerated in a brief period of time after animal awakening. In
these animals, a physiologically adaptive process associated with synaptic plasticity
seems to be supported by a reversible hyperphosphorylation of soluble Tau [78].
Furthermore, a small amount of Tau has been localized and accumulated in the
nuclear compartment, in both the soluble and chromatin-bound fractions. A puta-
tive role of Tau in both nucleolar organization and DNA damage protection and
chromosome stability have been proposed, since wild-type Tau prevents DNA
damage under oxidative stress or hyperthermic conditions. Recently, it has been
observed that promoting Tau nuclear translocation and accumulation, by Tau
overexpression or disengagement from MTs, enhances the expression of the vesic-
ular glutamate transporter VGluT1 [79], a disease-fundamental gene directly
involved in glutamatergic transmission. Significantly, the P301L mutation in Tau
gene, linked to frontotemporal dementia FTDP-17 [80], disturbs this mechanism
leading to a function loss. This fact demonstrates a direct physiological role of Tau
on modulating gene expression, particularly the expression of the vesicular gluta-
mate transporter VGluT1, which is known to be strongly upregulated in early
phases of tauopathies. Thus, alterations of this mechanism may be at the basis of the
onset of neurodegeneration.
Taken together, though most current approaches to target Tau are based on its
actions on MTs and are aimed at counteracting the aggregation of its soluble pool,
unlinked functions of Tau to its MT-binding properties have been suggested lately.
Therefore, in view of the evidence supporting considerable modulatory and poten-
tially protective functions of Tau at physiological conditions, the strategies aimed at
modulating the amount and modification of Tau should be carefully taken into
consideration when planning Tau-based therapies.
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7. The signaling pathway of the Wnt protein family
In humans, Wnts are a family of secreted glycolipoproteins (19 members) that
are evolutionarily conserved [81]. Wnts are essential for axon pathfinding, den-
dritic development, and the formation and function of synapses [82]. The contri-
bution of Wnts to synapse development in different model systems has been
supported widely [83].
Several Wnt proteins (Wnt7a, Wnt5a, and Wnt3a) that signal through different
receptors promote pre-synaptic differentiation [84]. Besides, Wnts signaling
promotes excitatory synapse formation and spine growth [85]. Unlike Wnt7a,
Wnt5a promotes inhibitory post-synaptic assembly by increasing GABAA receptor
clustering and enhancing the amplitude of inhibitory postsynaptic currents [86].
Members of the Wnt family might regulate excitatory and inhibitory post-synaptic
properties, differentially. Moreover, Wnts act bidirectionally to promote the
assembly of both sides of the synapse [84].
Regulation of synaptic transmission by Wnt proteins has been demonstrated by
electrophysiological recordings. Members of the Wnt family can modulate neuro-
transmission pre-synaptically and post-synaptically [84]. For instance, gain of
function of Wnt7a has shown to promote transmitter release in cultured neurons.
Post-synaptically, Wnt7a enhances synaptic strength by increasing the number of
AMPA receptors at the post-synaptic membrane in hippocampal neurons and
Wnt5a potentiates post-synaptic NMDAR-mediated currents through RoR2 recep-
tors in hippocampal neurons.
Members of the Wnt family are regulated by neuronal activity. Thus, neuronal
activity modulates the mRNA and protein levels of Wnts and their receptors in
different model systems. Wnt blockade completely abolishes activity-mediated
synapse formation in cultured neurons [87]. Blockade of endogenous Wnt proteins,
with secreted frizzled-related proteins (Sfrps), severely impairs LTP [88].
Conversely, addition of Wnt proteins can facilitate LTP [89].
Research is been currently focused on identifying the mechanisms by which
Wnts modulate LTP. In this regard, Wnt5a has been shown to regulate NMDAR-
mediated synaptic transmission in acute hippocampal slices [89]. However, it does
not affect endogenous synaptic AMPAR localization or dendritic spine size in hip-
pocampal cultured neurons [88]. Then, it is suggested that Wnt5a may contribute to
later stages of LTP.
Endogenous Wnt signaling is required for structural and functional plasticity
during LTP as it has been demonstrated. A study shows that Wnt7a/b regulate the
early stages of NMDAR-dependent LTP [88]. Acute blockade of endogenous Wnts
with Sfrps attenuates LTP induced by stimulating acute hippocampal slices at high
frequency or LTP induced by glycine application in hippocampal neurons. Changes
in dendritic spine structure, augmented synaptic strength, and synaptic localization
of AMPA receptors are inhibited in the presence of Sfrps during LTP. Intriguingly,
gain of function via single-particle tracking and super-ecliptic pHluorin-tagged
AMPA receptors in hippocampal neurons has proven that Wnt7a quickly enhances
dendritic spine growth, recruitment of synaptic AMPA receptors, and synaptic
strength, similar to the early phases of LTP [88].
A proper balance between canonical and non-canonical Wnt signaling might
determine whether synapses are lost or only their function is affected [84]. A mouse
model characterized by a Wnt deficiency in the adult brain has demonstrated that
Wnt proteins constitute a requirement for synapse stability and synaptic plasticity
[90]. Transgenic mice expressing the Wnt antagonist Dickkopf-1 (Dkk1) protein in
hippocampus display a loss of excitatory synapses, altered LTP, enhanced LTD, and
deficits in long-term memory [91]. Acute blockade of endogenous Wnts by Sfrps
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mate transporter VGluT1, which is known to be strongly upregulated in early
phases of tauopathies. Thus, alterations of this mechanism may be at the basis of the
onset of neurodegeneration.
Taken together, though most current approaches to target Tau are based on its
actions on MTs and are aimed at counteracting the aggregation of its soluble pool,
unlinked functions of Tau to its MT-binding properties have been suggested lately.
Therefore, in view of the evidence supporting considerable modulatory and poten-
tially protective functions of Tau at physiological conditions, the strategies aimed at
modulating the amount and modification of Tau should be carefully taken into
consideration when planning Tau-based therapies.
34
Biogenic Amines in Neurotransmission and Human Disease
7. The signaling pathway of the Wnt protein family
In humans, Wnts are a family of secreted glycolipoproteins (19 members) that
are evolutionarily conserved [81]. Wnts are essential for axon pathfinding, den-
dritic development, and the formation and function of synapses [82]. The contri-
bution of Wnts to synapse development in different model systems has been
supported widely [83].
Several Wnt proteins (Wnt7a, Wnt5a, and Wnt3a) that signal through different
receptors promote pre-synaptic differentiation [84]. Besides, Wnts signaling
promotes excitatory synapse formation and spine growth [85]. Unlike Wnt7a,
Wnt5a promotes inhibitory post-synaptic assembly by increasing GABAA receptor
clustering and enhancing the amplitude of inhibitory postsynaptic currents [86].
Members of the Wnt family might regulate excitatory and inhibitory post-synaptic
properties, differentially. Moreover, Wnts act bidirectionally to promote the
assembly of both sides of the synapse [84].
Regulation of synaptic transmission by Wnt proteins has been demonstrated by
electrophysiological recordings. Members of the Wnt family can modulate neuro-
transmission pre-synaptically and post-synaptically [84]. For instance, gain of
function of Wnt7a has shown to promote transmitter release in cultured neurons.
Post-synaptically, Wnt7a enhances synaptic strength by increasing the number of
AMPA receptors at the post-synaptic membrane in hippocampal neurons and
Wnt5a potentiates post-synaptic NMDAR-mediated currents through RoR2 recep-
tors in hippocampal neurons.
Members of the Wnt family are regulated by neuronal activity. Thus, neuronal
activity modulates the mRNA and protein levels of Wnts and their receptors in
different model systems. Wnt blockade completely abolishes activity-mediated
synapse formation in cultured neurons [87]. Blockade of endogenous Wnt proteins,
with secreted frizzled-related proteins (Sfrps), severely impairs LTP [88].
Conversely, addition of Wnt proteins can facilitate LTP [89].
Research is been currently focused on identifying the mechanisms by which
Wnts modulate LTP. In this regard, Wnt5a has been shown to regulate NMDAR-
mediated synaptic transmission in acute hippocampal slices [89]. However, it does
not affect endogenous synaptic AMPAR localization or dendritic spine size in hip-
pocampal cultured neurons [88]. Then, it is suggested that Wnt5a may contribute to
later stages of LTP.
Endogenous Wnt signaling is required for structural and functional plasticity
during LTP as it has been demonstrated. A study shows that Wnt7a/b regulate the
early stages of NMDAR-dependent LTP [88]. Acute blockade of endogenous Wnts
with Sfrps attenuates LTP induced by stimulating acute hippocampal slices at high
frequency or LTP induced by glycine application in hippocampal neurons. Changes
in dendritic spine structure, augmented synaptic strength, and synaptic localization
of AMPA receptors are inhibited in the presence of Sfrps during LTP. Intriguingly,
gain of function via single-particle tracking and super-ecliptic pHluorin-tagged
AMPA receptors in hippocampal neurons has proven that Wnt7a quickly enhances
dendritic spine growth, recruitment of synaptic AMPA receptors, and synaptic
strength, similar to the early phases of LTP [88].
A proper balance between canonical and non-canonical Wnt signaling might
determine whether synapses are lost or only their function is affected [84]. A mouse
model characterized by a Wnt deficiency in the adult brain has demonstrated that
Wnt proteins constitute a requirement for synapse stability and synaptic plasticity
[90]. Transgenic mice expressing the Wnt antagonist Dickkopf-1 (Dkk1) protein in
hippocampus display a loss of excitatory synapses, altered LTP, enhanced LTD, and
deficits in long-term memory [91]. Acute blockade of endogenous Wnts by Sfrps
35
Homeostatic Plasticity and Therapeutic Approaches in Neurodegeneration
DOI: http://dx.doi.org/10.5772/intechopen.86415
does not affect the number of excitatory synapses but inhibits LTP induction. This
is not due to acute versus long-term exposure to Wnt antagonists, as Dkk1 also
rapidly induces synapse loss in mature neurons [92]. Both antagonists have a dif-
ferent mechanism of action. While Sfrps inhibits Wnt function by means of binding
to Wnt proteins, Dkk1 affects a canonical Wnt signaling pathway by blocking the
low density lipoprotein receptor-related protein 6 (LRP6), an essential Wnt
co-receptor.
Growing evidence suggests that deficient Wnt signaling affects synaptic integ-
rity in the adult brain. In AD, particularly, decreased levels of Wnt signaling could
weaken synaptic function resulting in the subsequent degeneration and loss of
synapses characteristic of this condition. Expression of the endogenous Wnt antag-
onist Dkk1 is increased in the brain of AD patients. On other hand, Aß quickly
induces Dkk1 expression and blockade of Dkk1 protects synapses from Aß [92].
Besides, a variant of LRP6 has been linked to late onset AD [93] and deletion of
LRP6 magnifies pathology in an AD mouse model [94]. These findings along with
those obtained from mice expressing Dkk1 [91] demonstrate that deficits in Wnt
signaling affect synaptic integrity in the adult brain. In AD, diminished levels of
Wnt signaling could mine synaptic function leading to the subsequent degeneration
and synapse loss which is characteristic of this condition. Reactivation of Wnt
signaling might restore connectivity after substantial synapse degeneration. In fact,
the ceasing of Dkk1 expression in transgenic mice that express Dkk1 fully restores
the structural and functional plasticity and hippocampal-dependent memory [91].
Together, these studies prove the regenerative capacity of neurons in the adult
hippocampus to assemble synapses within functional circuits after degeneration.
8. Extracellular vesicles in the intercellular communication
In the CNS, extracellular vesicles (EVs) have emerged as key players in the
intercellular communication that underlies physiological processes such as synaptic
plasticity, maintenance of myelination, and neuronal and glial response to brain
injury. EVs are secreted membrane-enclosed ‘packages’ that contain cytosolic pro-
teins, membrane proteins, mRNAs, noncoding RNAs, and even DNA [95].
In order to modulate synaptic plasticity, neuronal EVs can transfer cargo to
other neurons. It has been suggested an uptake of neuronal EVs by microglia to
enhance microglial pruning of synapses. Moreover, increased astrocytic uptake of
glutamate may result from internalization of neuronal EVs into astrocytes. In turn,
EVs from astrocytes have been shown to contain cargo-mediating neuroprotection
under neuronal stress. Oligodendrocyte-derived EVs increase neuronal firing medi-
ate as well as neuronal stress resilience [96]. Moreover, oligodendrocyte-derived
EVs may behave as auto-inhibitors in expansion of myelin. As for microglial EVs,
they may modulate neuronal firing, and also propagate inflammation and destabi-
lize synapses in a CNS injury setting. In terms of neurodegenerative diseases, EVs
are involved in both the spreading and clearance of neurotoxic protein aggregates
[97]. EVs have also been shown to cross the blood-brain barrier particularly under
inflammatory conditions, enabling molecular crosstalk between brain cells and the
periphery [98].
The coupling of neuronal EV release to synaptic activity could be functionally
relevant for plasticity-associated processes. For instance, activity-dependent dis-
posal or transfer of AMPA receptor components, which have been shown to flow
throughout EVs, may constitute a mechanism for the adjustment of synaptic
strength [99]. Moreover, it has been suggested that neuronal EVs act as trans-
synaptic carriers of signaling proteins involved in synaptic plasticity. In a series of
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in vivo studies at the Drosophila neuromuscular junction, it has been shown that the
Wnt-family signaling protein Wingless was protected driving toward EVs by the
trafficking protein Evi/Wntless for trans-synaptic transport and hampering this
trafficking impaired synaptic bouton formation [100]. In the same model system,
synaptotagmin 4 has been found to drive on EVs from the presynaptic motor
neuron to the postsynaptic muscle, and this directional transport was fundamental
for activity-dependent growth of presynaptic structures.
Plasticity-associated local protein synthesis at synapses appears to be affected by
the activity-dependent trafficking of specific RNAs into EVs. In one study, depo-
larization of differentiated neuroblasts has been found to be correlated with a
depletion of specific miRNAs from neurites, associated with an enhancement of a
specific subset of these miRNAs in EVs. Furthermore, neuronal EVs have been
recently shown to package mRNA in association with the activity-regulated
cytoskeleton-associated protein (Arc), described as a master regulator of synaptic
plasticity [101]. Arc appeared to self-assemble into capsids as if it were a viral
group-specific antigen (Gag) protein, encapsulating its own mRNA or other highly
abundant mRNAs, and trafficking between cells by means of EVs. The blockage of
Arc trafficking from presynaptic terminals to the postsynaptic muscle, at the Dro-
sophila neuromuscular junction, caused aberrations in synapse maturation and
activity-dependent plasticity [102]. Therefore, Arc capsid-containing EVs may
constitute a retrovirus-like mechanism for trans-synaptic transfer of at least Arc
mRNA during processes associated with synaptic plasticity. The biological origin
and composition of Arc-containing EVs, as well as the scope of the EV-associated
Arc transport in the mammalian brain, have yet to be studied in the future.
It is intriguing that neuronal EVs can also transfer cargo to other cells in the
brain, modulating their behavior with a potential impact on synaptic activity. One
study found that the uptake of neuronal miR-124a-carrying EVs into astrocytes was
correlated with overexpression of excitatory amino acid transporter 2/glutamate
transporter-1 (EAAT2/GLT1), which could modulate synaptic activity via an
increased uptake of glutamate into perisynaptic astrocytes [103]. Moreover, EVs
from differentiated PC12 cells seemed to promote microglial phagocytosis of
degenerating neurites by means of increasing the microglial expression of comple-
ment component 3 (C3), a factor associated with synaptic pruning. The release of
EVs from active neurons could thereby serve to the removal of less functional
synapses during developmental or learning-associated remodeling of neuronal
connections, although validation of this finding is warranted in at least primary
neurons.
With regard to glial EVs, they have been described to provide neurons with
support and feedback on synaptic activity. And so, for example, oligodendrocytes
contain multivesicular endosomes at sites near the axonal surface, and secrete EVs
particularly in response to glutamate. While microglia appeared to degrade
oligodendrocyte-derived EVs, neuronal internalization of these EVs led to func-
tional cargo retrieval along with an increase in neuronal firing rate and modified
gene expression of several plasticity-related targets, such as VGF nerve growth
factor inducible and BDNF [104]. Microglial microvesicles (MVs), for its part,
released in response to ATP and increased excitatory neurotransmission through
stimulation of neuronal sphingolipid metabolism and a consequent increase in the
presynaptic release of neurotransmitters. The functionality of the MVs seemed to
depend on a lipid or a surface component since sheared MVs retained the function-
ality [105]. In another study, microglial EVs have shown to carry the active
endocannabinoid N-arachidonoylethanolamine on their surface, which bound to
presynaptic type 1 cannabinoid receptors, and thereby decreased the release of the
neurotransmitter GABA. Overall, glial EVs seem to influence both excitatory and
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inhibitory neurotransmission, providing regulatory feedback particularly on pre-
synaptic activity [95].
As remarkable, EVs have emerged as possible therapeutic agents in
inflammation-mediated demyelinating diseases, such as multiple sclerosis (MS).
Increasing evidence suggests that EVs display anti-inflammatory properties,
reducing the number of activated inflammatory microglial cells, supporting oligo-
dendrocytes and protecting neurons. A very recent study illustrates a putative
therapeutically role for EVs. Intravenously administered EVs derived from mesen-
chymal stem cells (MSCs) from human adipose tissue might mediate recovery in
Theiler’s murine encephalomyelitis virus (TMEV)-induced demyelinating disease, a
progressive model of MS [106]. Intravenous EV administration in SJL/J mice
improved motor deficits, lowered brain atrophy, enhanced cell proliferation in the
subventricular zone, and decreased inflammatory infiltrates in the spinal cord of
animals infected with TMEV. In addition, EV treatment was capable of modulating
neuroinflammation, given glial fibrillary acidic protein and Iba-1 staining were
reduced in the brain, whereas the expression of myelin was increased. Modifica-
tions of morphology in microglial cells from the spinal cord may indicate that EVs
also modulate the activation state of microglia. EV administration attenuates motor
deficits through immunomodulatory actions, diminishing brain atrophy and pro-
moting remyelination.
So far, there is no evidence regarding the therapeutic potential of EVs during the
neurodegenerative phase of MS. Further studies are necessary to establish EV
delivery as a possible therapy for the neurodegenerative phase of MS.
9. Estrogen involvement in non-reproductive functions
Estrogens from neural origin are involved in a variety of non-reproductive
functions including regulation of neurogenesis, neuronal development, synaptic
transmission, and plasticity in brain regions not directly related with the control of
reproduction [107]. Estrogens regulate the expression of genes for various specific
subtypes of dopamine (DA) receptors and 5-HT receptors in a region-specific
manner to contribute to behavioral responses to changes of the internal and external
environment.
DA neurotransmission of the ventral tegmental area (VTA)-nucleus accumbens
(NAc) pathway associated with motivation is modulated by estrogens, which
results in functional differences of the mesolimbic dopaminergic pathway and
explains numerous sex differences in reward processing and related behavior
described in human and animal studies [108]. Generally, increased circulating levels
of estrogens in rodents, either during their estrous cycles or by estrogen treatment,
have shown to contribute to elevated dopaminergic signaling. Estrogens influence
manifold aspects of dopaminergic neurotransmission both presynaptically and
postsynaptically, including: (a) DA synthesis, release, and degradation; (b) presyn-
aptic and postsynaptic receptors; and (c) DA transporters that uptake DA from the
synapse to terminate DA neurotransmission. Nuclear and membrane-associated
estrogen receptors (ERs) may constitute the mechanisms by which estrogens affect
the dopaminergic system. Precisely, ERs are distributed in dopaminergic pathways
involved in reward, what is pertinent to the effects of estrogens on the CNS reward
system [109]. In male mice, dopaminergic projections from the VTA to the ventral
caudate express the ERβ isoform, while dopaminergic projections to the dorsal
caudate do not. Dopaminergic projections to the basolateral amygdala also express
ERβ. Estrogens also act rapidly through membrane-associated ERs on dopaminergic
neurons in the striatum to affect DA release. Estrogens increase the activity of the
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tyrosine hydroxylase (TH) and thus DA synthesis in the NAc by means of both
nuclear ERs and membrane ER; induce presynaptic DA release in the striatum; and
decrease DA turnover in the NAc and reduce degradation of DA so that DA remains
longer at the synapse [108].
Estrogens upregulate the expression and activity of tryptophan hydroxylase
(TPH) to increase 5-HT biosynthesis. Estrogen administration has been found to
increase the TPH mRNA level [110]. In ovariectomized (OVX) guinea pigs, estro-
gen treatment alone increases the protein expression of TPH at the dorsal raphe
nucleus (DRN). Surprisingly, while treatment with estrogen alone increases levels
of TPH mRNA and TPH protein, it does not modify 5-HT content; rather, the
treatment combining estrogen plus progesterone enhances 5-HT levels at both the
DRN and the projected medial basal hypothalamus in guinea pigs [111]. Thus, there
is a disparity in the sex hormone regulation of TPH mRNA and TPH protein levels
versus 5-HT production in estrogen-treated animals, likely due to activity of TPH
that is regulated by means of phosphorylation by protein kinase A (PKA) [112].
Since only phosphorylated TPH possesses catalytic activity, progesterone treatment
might increase PKA expression and activity of TPH. After loss of ovarian function
in many women, there may be an adjustment in the serotonergic neurons so that
TPH protein levels recover. This also may indicate that the decline in TPH expres-
sion is a potential point of vulnerability in pre- and postmenopausal women who
experience mental disorders such as depression related to the decreased level of
5-HT.
Estrogens regulate the 5-HT receptors, 5-HT2A and 2C, which display classic
features of G protein-coupled receptors. The 5-HT2A receptor has been associated
with suicide and depression, and its mRNAs are found in brain areas fundamental
for the mood control, mental state, and cognition [113]. In humans, 5-HT2A recep-
tor mRNA is found in the cortex and hippocampus, but not in the DRN, striatum,
substantia nigra, or cerebellum [114]. Estrogens increase 5-HT2A receptor mRNA
and binding site densities in the male rat brain. Healthy men have shown signifi-
cantly higher levels of 5-HT2A receptor binding capacity than healthy women in the
frontal and cingulate cortices, according to determinations by PET and radiotracer
18F-labeled altanserin [115]. Human studies suggest that estrogens increase 5-HT2A
binding in higher forebrain regions.
The NAc receives major inputs from the amygdala and projects to the cortex and
hypothalamus. These regions are fundamental for the cognitive function, emotion,
mental state, mood, and neuroendocrine control. Thus, increase in 5-HT2A receptor
densities by estrogen stimulation in these stated regions would control behavior and
mood. A single administration of estradiol to OVX rats induces a significant increase
in 5-HT2A receptor labeling in the NAc, the amygdala, DRN, anterior frontal,
anterior cingulate, and primary olfactory cortex [116]. Moreover, concomitantly
with the spontaneous estrogen-induced LH surge, 5-HT2A receptor densities
increase compared to diestrous females or males in the frontal and cingulate cortex,
olfactory tubercle and NAc. OVX produces a reduction of 5-HT2A receptor mRNA
and protein levels, and long-term estrogen replacement reverses this effect in the
frontal cortex [117]. The receptor 5-HT2C, a relevant contributor of many psychi-
atric and neurological disorders, is the most prominent 5-HT receptor subtype in
the rat brain. 5-HT2C mRNA and protein are found in discrete regions of the rat
brain. In the primate hypothalamus, dense populations of 5-HT2C mRNA-labeled
cells are found in the anterior hypothalamus, periventricular nuclei, ventromedial
nucleus, dorsal hypothalamic area, lateral hypothalamus, arcuate nucleus, and
infundibular nucleus [118].
Estrogens regulate 5-HT auto-inhibition via the 5-HT1A auto-receptor. The
5-HT1A auto-receptor suppresses 5-HT synthesis by inhibiting firing of
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inhibitory neurotransmission, providing regulatory feedback particularly on pre-
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serotonergic neurons at the DRN and median raphe and inhibiting 5-HT release in
the hippocampus [119]. Therefore, the blockage of 5-HT1A receptors results in an
antidepressant-like activity. Estrogen treatment lowers the 5-HT1A mRNA level
in the dentate gyrus, CA2 region of the hippocampus, and DRN of OVX rats and in
the DRN and median raphe of castrated rhesus monkeys, according to measurement
by in situ hybridization. The5-HT1A auto-receptor is linked to an inhibitory
G protein of the Gi/o/zfamily [120].
Estrogen treatment reduces 5-HT uptake to presynaptic cells by means of
decreasing gene expression, translation, protein phosphorylation, trafficking, and
stability of the serotonin transporter (SERT) [121]. Estrogens reduce SERT mRNA
signal in the DRN of castrated rhesus monkeys treated with estrogen compared to
the castrated control group and decrease [3H]-paroxetine binding, a selective indi-
cator of 5-HT reuptake sites, in the hippocampus of estrogen-treated rats. Acute
estrogen administration decreases SERT mRNA levels and 5-HT1A mRNA levels
and binding. Thus, estrogen replacement therapy in postmenopausal women might
decrease expression of the SERT gene and SERT protein [107]; thus 5-HT may
remain longer in the extracellular space to continue neurotransmission. However,
such argument does not support the observations that humans with depression have
lower levels of 5-HT reuptake sites than healthy humans [122]. It might be that
there is a mitigated 5-HT release and reduced levels of 5-HT in humans with
depression to begin with, and a less 5-HT reuptake [107].
As we described, estrogens enhance 5-HT signaling via increasing 5-HT biosyn-
thesis, upregulating expression and binding of receptors 5-HT2A and 5-HT2c,
downregulating activity and expression of the 5-HT1A auto-receptor, decreasing
expression of SERT gene and SERT protein allowing 5-HT to remain in the extra-
cellular space for a longer period of time to continue neurotransmission, and
decreasing 5-HT metabolism [107]. Consequently, the hypothesis of estrogen pro-
tection [123] claims that adjunctive estrogen treatment is beneficial at improving
both symptoms of schizophrenia and the cognitive function, most notably in
women. So far, the majority of studies on hormone replacement therapy for mood
disorders have shown a positive response. Thus, estrogen has been demonstrated to
improve mood in multiple mental illnesses, including major depressive disorder.
Most recently, adjunctive estradiol treatment has been suggested as a promising
treatment for women with comorbid depression and schizophrenia. In this direc-
tion, exploration of the impact of estrogen on serotonergic and other neurochemical
pathways plus brain circuitry may guide not only the development of new hormone
treatments but also assist in understanding the etiology of premenstrual dysphoric
disorder, postnatal and perimenopausal depression, and even schizophrenia in
women.
On the other hand, estrogens have shown that they do not always improve
learning and memory. As an experimental example, acute administration of high
doses of 17β-estradiol and progesterone can impair performance in the memory test
of Morris water maze. And most importantly, there is coherence among human
studies since high endogenous levels of 17β-estradiol are associated with poor per-
formance on spatial tasks and cognitive function (Montreal Cognitive Assessment
scale) and high dose of exogenous 17β-estradiol impairs recognition memory. It is
fundamental to assume that estradiol exerts a curvilinear influence on
hippocampal-dependent performance, with low and high levels impairing versus a
medium dose improving performance on a variety of tasks [124]. Similar dose
response has been observed in the rapid effects of estrogens on dendritic spines,
therefore, studies on the effects of estrogens on cellular morphology should take
dose response into account. Furthermore, long-term exposure to estrogens can
similarly result in dose-dependent responses on learning and memory, with low
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levels of 17β-estradiol reinforcing spatial working memory and high levels of estra-
diol hampering spatial working and reference memory. Studies have also shown
that, whereas there is a dose-dependent facilitation in contextual fear conditioning
by 17β- and 17α-estradiol, estrone results in dose-dependent impairments in con-
textual fear conditioning. Thus, it is essential to consider that the dose, frequency of
administrations, and type of estrogen(s) utilized along with the type of memory
task performed and the time point estrogens are administered (during acquisition
or retrieval), are critical to the learning outcomes [124].
10. Conclusion
This review has concentrated on some cellular processes and signaling pathways
acting during homeostatic molecular remodeling and their potential involvement in
the maladaptive plasticity occurring in multiple neuropathologic conditions such as
neurodegeneration and neuropsychiatric disorders.
There seem to be independent mechanisms for regulating presynaptic and post-
synaptic strength, and there is evidence for independent homeostatic mechanisms
operating on global and local spatial scales.
Involvement of different pharmacological approaches to compensate neuro-
transmission imbalance are under study, which may be considered as potential
therapeutic approaches in neuropathologic conditions.
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Abstract
Herbs have many biologically and pharmacologically active compounds such as 
flavonoids and stilbenes. They have been used in remedies for various disorders. 
Here we review the effects of herbs on catecholamine synthesis and secretion in cul-
tured bovine adrenal medullary cells. Ikarisoside A (1.0–100 μM), a flavonol glyco-
side, inhibited the catecholamine secretion induced by acetylcholine (0.3 mM). This 
inhibition was associated with the suppression of 22Na+ and 45Ca2+ influx induced 
by acetylcholine. The ethanol extract (0.0003–0.005%) of matsufushi (extract 
of pine nodules) inhibited the catecholamine secretion induced by acetylcholine. 
SJ-2, one of the stilbene compounds isolated from matsufushi, inhibited acetyl-
choline-induced catecholamine secretion. Matsufushi extract and SJ-2 reversibly 
inhibited acetylcholine-induced Na+ currents in Xenopus oocytes expressed with 
α3β4nicotinic acetylcholine receptors. Sweet tea is the processed leaves of Hydrangea 
macrophylla. The extract of sweet tea (0.3–1.0 mg/ml) suppressed catecholamine 
secretion induced by acetylcholine (0.3 mM). Moreover, sweet tea (0.1–1.0 mg/ml), 
ikarisoside A (1.0–100 μM), and matsufushi (0.001–0.003%) or SJ-2 (10–30 μM) 
inhibited acetylcholine-induced 14C-catecholamine synthesis from 14C-tyrosine. 
These findings indicate that ikarisoside A, matsufushi (or SJ-2), and sweet tea 
inhibit the catecholamine secretion and synthesis induced by acetylcholine in 
cultured bovine adrenal medullary cells and probably in sympathetic neurons.
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1. Introduction
Since herbs have many biologically and pharmacologically active compounds 
such as flavonoids and stilbenes, they have been used in remedies for various 
disorders. A high dietary intake of herbs has become a focus of research because 
of herbs’ potential to reduce the risks of diseases such as hypertension, coro-
nary heart disease, diabetes, and cancers [1, 2]. Flavonoids are a group of plant 
secondary metabolites with variable phenolic structures, and they are found in 
plants, fruits, vegetables, roots, stems, flowers, wine, and tea [3, 4]. Over 5000 
individual flavonoids have been reported [5], and 6 principal groups of flavonoids 
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(flavones, flavonols, flavanones, flavanols, isoflavones, and anthocyanidins) are 
relatively common in human diets [1]. Polyphenol stilbenes have attracted scientific 
attention. For example, resveratrol (trans-3,4′,5-trihydroxy- stilbene) is a natural 
phytoestrogen found in grapes, berries, and red wine [6, 7] that was reported to be 
implicated in the beneficial effect of red wine, i.e., the lower incidence of coronary 
artery disease in certain populations such as the French and the Greeks, despite 
diets rich in saturated fat and a rate of high smoking, which has been dubbed the 
“French paradox” [8].
In the human body, the most abundant catecholamines are adrenaline, nor-
adrenaline, and dopamine, all of which are produced from phenylalanine and/or 
tyrosine. Catecholamines are biosynthesized mainly in the adrenal medulla, the 
postganglionic fibers of the sympathetic nervous system, and the central nervous 
system [2, 9, 10]. Catecholamines play very important roles in aspects of the cardio-
vascular system such as heart rate and blood pressure, blood glucose levels, and the 
general functions of the central and peripheral sympathetic nervous system [9].
Adrenal medullary cells derived from embryonic neural crests are functionally 
homologous to sympathetic postganglionic neurons [2, 10]. Our research dem-
onstrated that in cultured bovine adrenal medullary cells, at least three distinct 
types of ionic channels participate in catecholamine secretion, including nicotinic 
acetylcholine receptor (nAChR)-ion channels, voltage-dependent Na+ chan-
nels, and voltage-dependent Ca2+ channels [2, 11]. In these cells, the Na+ influx 
induced by acetylcholine (ACh) via nAChR-ion channels or by veratridine via 
voltage-dependent Na+ channels is a prerequisite for Ca2+ influx via the activation 
of voltage-dependent Ca2+ channels and subsequent catecholamine secretion; in 
contrast, high K+ directly gates voltage-dependent Ca2+ channels to increase the 
Ca2+ influx without increasing the 22Na+ influx [10, 11] (Figure 1). ACh-induced 
Ca2+ influx is also a prerequisite for the stimulation of catecholamine synthesis 
associated with the activation of tyrosine hydroxylase [2, 12–15]. The mechanisms 
underlying the stimulation of catecholamine synthesis and secretion mediated by 
these ion channels in adrenal medullary cells are thought to be similar to those of 
Figure 1. 
The mechanism underlying the regulation of catecholamine synthesis, secretion, and reuptake in bovine adrenal 
medullary cells.
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noradrenaline in the sympathetic neurons and brain noradrenergic neurons [2]. 
Thus, adrenal medullary cells have provided a good model for the detailed analysis 
of antipsychotic [16], cardiovascular [17], and analgesic [18] drugs that act on 
catecholamine synthesis, secretion, and reuptake [2].
We have demonstrated the effects of several flavonoids and polyphenol stilbenes 
on catecholamine synthesis and secretion. For example, the treatment of bovine 
adrenal medullary cells with daidzein (an isoflavone derived from soy beans) 
stimulated basal catecholamine synthesis but inhibited the catecholamine synthesis 
and secretion induced by ACh [2, 19]. Genistein (another isoflavone in soy beans) 
but not daidzein stimulated the function of noradrenaline transporter in a human 
neuroblastoma cell line, SK-N-SH cells [2, 20]. Nobiletin (a compound of polyme-
thoxy flavone in citrus fruits) stimulated the basal synthesis and secretion of cat-
echolamines, but it suppressed both the ACh-induced synthesis of catecholamines 
and ACh-induced secretion of catecholamines [2, 21]. Resveratrol also inhibited the 
catecholamine synthesis and secretion induced by ACh [2, 22].
The present review summarizes our recent and current studies of the phar-
macological effects of herbs and their components, i.e., ikarisoside A (a flavonol 
glycoside); matsufushi (extract of pine nodules), one of matsufushi’s stilbene 
components (SJ-2); and sweet tea on the catecholamine signaling induced by ACh 
in cultured bovine adrenal medullary cells and on ACh-induced Na+ current in 
Xenopus oocytes expressing α3β4 nAChRs.
2. Inhibitory effects of ikarisoside A, but not its aglycon, on the 
catecholamine secretion and synthesis induced by ACh
Ikarisoside A is a natural flavonol glycoside derived from plants of the genus 
Epimedium, which have been used in traditional Chinese medicine as tonics, 
antirheumatics, and aphrodisiacs [10, 23, 24], and is used as a tonic supplement in 
Japan. Ikarisoside A has antioxidant and anti-inflammatory effects [23] and anti-
osteoporosis effects [10, 25]. Icariin, another flavonoid in the genus Epimedium, has 
an anti-stress effect in the forced swimming test in mice [26].
We observed that ikarisoside A (1–100 μM) concentration dependently inhibited 
the secretion of catecholamines induced by ACh (0.3 m) (Figure 2A), but not the 
secretion of catecholamines induced by veratridine and 56 mK+ [10]. Ikarisoside A 
also suppressed the 22Na+ influx and 45Ca2+ influx induced by ACh in a concentration-
dependent manner similar to that of catecholamine secretion (Figure 2B, C) [10] . 
Ikarisoside A is a flavonol glycoside with one rhamnose at the 3 position in the chemi-
cal structure. The aglycon of ikarisoside A is 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-
8-(3-methylbut-2-enyl)-4H-chromen-4one (Figure 3A).  
It is interesting to note that the aglycon of ikarisoside A had little effect on catechol-
amine secretion induced by ACh (0.3 m) (Figure 3B), suggesting that the rhamnose 
moiety at the 3 position of ikarisoside A is essential to inhibit the function of nAChR-
ion channels [10]. Ikarisoside A (1.0–100 or 10–100 μM) inhibited ACh (0.3 mM)-
induced 14C-catecholamine synthesis from 14C-tyrosine and tyrosine hydroxylase 
activity [10].
3. Inhibitory effects of matsufushi and its stilbene component, SJ-2,  
on the catecholamine synthesis and secretion induced by ACh
Pine nodules of Pinus tabulaeformis or Pinus massoniana are formed by pine bark 
proliferation at places on the trunk or limbs that have undergone damage, either 
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Figure 2. 
Effects of ikarisoside A on ACh-induced catecholamine secretion (A), 45Ca2+ influx (B), and 22Na+ influx (C). 
(A) Cultured bovine adrenal medullary cells (106/well) were stimulated with ACh (300 μM) in the presence or 
absence of ikarisoside A (0.3–100 μM) for 10 min at 37°C. Catecholamine secretion is expressed as a percentage 
of the total catecholamines in the cells. (B and C) Cells (4 × 106/well) are stimulated with ACh (300 μM) and 
1.5 μCi of 45CaCl2 (B) or 22NaCl (C) in the presence or absence of ikarisoside A (0.3–100 μM) for 5 min at 
37°C. 45Ca2+ influx and 22Na+ influx were expressed as nmol/4 × 106 cells. Data are means ± SEM from three 
separate experiments carried out in triplicate. **P < 0.01 and ***P < 0.001 vs. ACh alone (by one-way ANOVA 
with Dunnett’s multiple comparison post hoc test) (cited from [25]).
Figure 3. 
Structures of ikarisoside A and its aglycon (A) and the effect of aglycon of ikarisoside A on the catecholamine 
secretion induced by ACh (0.3 mM) (B). (A) Chemical structures of ikarisoside A and its aglycon 
(3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8- (3-methylbut-2-enyl)-4H-chromen-4-one). (B) Cells (106/
well) were incubated with or without aglycon of ikarisoside A (1–100 μM) and ACh (300 μM) for 10 min 
at 37°C. Catecholamine secretion is expressed as a percentage of the total. Data are means ± SEM from three 
separate experiments carried out in triplicate (cited from [25]).
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by pests or physical injury [27]. The effective curative components in pine nodule 
extract (matsufushi) have been used as an analgesic for joint pain, rheumatism, 
neuralgia, dysmenorrhea, and other complaints in traditional Chinese medicine 
[27–29]. Matsufushi is used as a healthy supplement in Japan.
Matsufushi ethanol extract (0.0003–0.005%) concentration dependently inhibited 
the catecholamine secretion and 45Ca2+ influx induced by ACh (0.3 mM) and veratridine 
(0.1 mM), but not 56 mM K+ in cultured bovine adrenal medullary cells [27]. Four com-
pounds (SJ-2, SL-3, SJ-4, and SJ-16) were isolated from matsufushi extract (Figure 4). 
SJ-2, a phenol stilbene, and the mixture of four compounds (Mix4; SJ-2, SJ-3, SJ-4, and 
SJ-16), but not each of the other separate compounds, inhibited the catecholamine secre-
tion (Figure 5) and 45Ca2+ influx [27] induced by ACh (0.3 mM). In Xenopus oocytes 
Figure 4. 
Chemical structures of SJ-2, SJ-3, SJ-4, and SJ-16 (cited from [28]).
Figure 5. 
Effects of SJ-2, SJ-3, SJ-4, SJ-16, and their mixture (Mix4) on catecholamine secretion induced by ACh 
in cultured bovine adrenal medullary cells. The cells (106/well) were incubated with or without SJ-2 
(10 μM), SJ-3 (10 μM), SJ-4 (10 μM), C-16 (10 μM), and their mixture (Mix 4) (10 μM) for 10 min at 
37°C. Catecholamine secretion is expressed as a percentage of the total catecholamines in the cells. Data are 
means ± SEM from three separate experiments carried out in triplicate. ***P < 0.001 vs. ACh alone. Rha: 
rhamnose (cited from [28]).
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37°C. Catecholamine secretion is expressed as a percentage of the total catecholamines in the cells. Data are 
means ± SEM from three separate experiments carried out in triplicate. ***P < 0.001 vs. ACh alone. Rha: 
rhamnose (cited from [28]).
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expressed with α3β4 nAChRs, matsufushi extract and SJ-2 reversibly inhibited ACh 
(0.2 mM)-induced Na+ currents (Figure 6A, C). Matsufushi extract (0.00003–0.001%) 
(Figure 6B) and SJ-2 (1–100 μM) (Figure 6D) significantly suppressed the Na+ current 
in a concentration-dependent manner [27]. In addition, matsufushi and SJ-2 suppressed 
the ACh (0.3 mM)-induced 14C-catecholamine synthesis from 14C-tyrosine and tyrosine 
hydroxylase activity [27]. These results suggest that matsufushi extract inhibits ACh-
induced catecholamine synthesis and secretion mainly due to SJ-2 via the suppression of 
Na+ influx mediated through nAChR-ion channels [27].
4. Effects of the extract of sweet tea on catecholamine secretion and 
synthesis in adrenal medullary cells
Sweet tea is the processed leaves of Hydrangea macrophylla var. thunbergii Makino 
(hydrangeae dulcis folium), which is listed in the Japanese Pharmacopeia XV and used 
as a sweetening agent for diabetic patients. It also has antimicrobial and anti-allergic 
Figure 6. 
Effects of ethanol extract of matsufushi and SJ-2 on inward currents induced by ACh in Xenopus oocytes 
expressing rat α3β4 nAChRs. Representative traces from a single Xenopus oocyte are shown. The currents of 
matsufushi-treated (A) and SJ-2-treated (C) oocytes were recorded for 10 min after recording of the control 
currents, and the washout currents were obtained for 10 min after matsufushi extract and SJ-2 treatment. 
Matsufushi extract (0.0001%) and SJ-2 (10 μM) suppressed the currents induced by the EC50 (0.2 mM)  
of ACh, and the inhibitory effects were reversible. Concentration-response curve for the inhibitory effects of 
matsufushi extract (B) and SJ-2 (D) on ACh-induced currents. The peak current amplitude in the presence of 
matsufushi extract and SJ-2 was normalized to that of the control, and the effects are expressed as percentages 
of the control. Data are presented as means ± SEM from four separate experiments carried out in triplicate. 
*P < 0.05 and ***P < 0.001 vs. the control (cited from [28]).
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effects [30, 31]. Sweet tea is used as a healthy tea in Japan. There is, however, little 
evidence regarding sweet tea’s effects on the sympathetic nervous system activity.
We investigated the effects of the extract of sweet tea on adrenal medullary cell 
function. A dry powder of sweet tea prepared from fermented leaves of hydrangeae 
dulcis folium was solubilized at 5.0 mg/ml and extracted at 90°C for 60 min. The 
extracted solution of sweet tea was used after centrifugation and filtration. The 
extract of sweet tea (1.0 mg/ml) slightly increased the basal secretion of catechol-
amines (Figure 7A), whereas it suppressed the catecholamine secretion induced by 
ACh (0.3 mM) in a concentration-dependent manner (300–1000 μg/ml) (Figure 7A). 
In addition, the extract of sweet tea (300– or 100–1000 μg/ml) inhibited basal and 
ACh (0.3 mM)-induced 14C-catecholamine synthesis from 14C-tyrosine, respectively 
(Figure 7B). Sweet tea at concentrations of 3 mg/ml is usually used for drinking.
5. The insight of pharmacological potential of herbs in the 
catecholamine signaling induced by ACh in adrenal medulla
Adrenal medullary cells are derived from the embryonic neural crest and share 
many physiological and pharmacological properties with postganglionic sympathetic 
Figure 7. 
Effects of sweet tea on 14C-catecholamine synthesis from [14C]tyrosine (A) and tyrosine hydroxylase activity 
(B) in the cells. (A) Cells (4 × 106/dish) were incubated with L-[U-14C] tyrosine (20 μM, 1 μCi) in the 
presence or absence of sweet tea (100–1000 μg/ml) and with or without 300-μM ACh at 37°C for 20 min. 
The 14C-catecholamines formed were measured. (B) Cells (106/well) were incubated with L-[1-14C] tyrosine 
(18 μM, 0.2 μCi) in the presence or absence of sweet tea (100–1000 μg/ml) and with or without 300 μM ACh at 
37°C for 10 min, and tyrosine hydroxylase activity was measured. Data are means ± SEM from three separate 
experiments carried out in triplicate. *P < 0.05, compared with 37°C (control), and **P < 0.01 and ***P < 0.001 
vs. ACh alone in (A), and **P < 0.01vs. 37°C (control) and ***P < 0.001 vs. ACh alone in (B).
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neurons [2]. The stimulation of AChRs in these cells increases the synthesis of catechol-
amines and causes the secretion of catecholamines into the systemic circulation [2, 11, 
14]. In adrenal medullary cells, the Na+ influx induced by ACh via nAChR-ion channels 
is a prerequisite for Ca2+ influx via the activation of voltage-dependent Ca2+ channels 
and the subsequent catecholamine secretion and synthesis; in contrast, high K+ directly 
gates voltage-dependent Ca2+ channels to increase 45Ca2+ influx [2, 11] (Figure 1).
As we noted, ikarisoside A and matsufushi (or SJ-2) inhibited the catecholamine 
secretion induced by ACh, but not the secretion induced by 56 mM K+ [10, 27]. In 
addition, ikarisoside A [10] and matsufushi [27] or SJ-2 [27] suppressed the Na+ 
current induced by ACh in Xenopus oocytes expressing α3β4 nAChRs. These results 
suggest that the herbs and their components used as described herein inhibit the 
ACh-induced secretion and synthesis of catecholamines via a suppression of Na+ 
influx mediated through nAChRs in adrenal medullary cells [10, 27].
It is well known that catecholamines have important roles in the regulation of 
normal function in the central and peripheral sympathetic nervous systems as a 
neurotransmitter but also in the adrenal medulla as an endocrine hormone [10]. 
Strong and prolonged stress causes massive amounts of catecholamine release, which 
can lead to cardiovascular diseases (such as hypertension, coronary heart disease, 
heart failure, and atherosclerosis), and such stress also suppresses the immune 
system to induce some cancers [2, 9, 10]. Indeed, chronic heart failure is associated 
with the activation of the sympathetic nervous system as manifested by an increased 
circulating level of noradrenaline and increased regional activity of the sympathetic 
nervous system [2, 32]. It was reported that the stress hormone adrenaline stimulates 
β2-adrenoceptors to activate the Gs-protein-dependent protein kinase A and the 
β-arrestin-1-mediated signaling pathway, which, in turn, suppresses p53 levels and 
triggers DNA damage [2, 33]. On the basis of these previous and present results, it 
appears that the herbs and their components such as ikarisoside A, matsufushi  
Figure 8. 
Inhibitory mechanism of plant herbs (ikarisoside A, matsufushi, and sweet tea) on stress or excitation-induced 
excessive catecholamine secretion. Prolonged and strong stress or excitation stimulates the brain cortex, limbic 
system, and hypothalamus which evoke acetylcholine release from the splanchnic sympathetic nerves. Released 
acetylcholine induces a massive secretion of catecholamines from the adrenal medulla which may cause 
various deleterious symptoms or diseases such as high blood pressure (hypertension), vasculature proliferation 
(atherosclerosis), blood coagulation (thrombus), immune suppression, and cancers ([2] modified).
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(or SJ-2), and sweet tea suppress the induction of a hyperactive catecholamine 
system induced by strong stress or emotional excitation (Figure 8).
6. Future perspective
Although the in vitro effects of the herbs and herb components described herein 
have been well clarified using cultured bovine adrenal medullary cells and Xenopus 
oocytes, the in vivo results are not yet clear. To confirm the pharmacological effects 
of these herbs on the catecholamine system, further in vivo studies of the effects of 
the administration of herbs to animals or humans are needed [2, 27]. We observed 
a disturbance of the autonomic nervous balance in women with climacteric symp-
toms measured by a power spectral analysis of heart rate variability [34]. Using 
this assay method, we will examine the effect of herbs on the autonomic nervous 
activity under some stress conditions.
7. Concluding remarks
We have reviewed the evidence that herbs and their components such as ikariso-
side A, matsufushi (or SJ-2), and sweet tea inhibit the catecholamine synthesis and 
secretion induced by ACh in cultured bovine adrenal medullary cells and summarized 
them in Table 1. These findings may provide new insights into the pharmacological 
potentials of herbs on the hyperactive catecholamine system induced by stress.
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Thrombotic Tendencies in Excess 
Catecholamine States
Vivek K. Nambiar and Drisya Rajan Chalappurath
Abstract
Catecholamines are neurotransmitters distributed throughout the body including 
adrenal glands, chromaffin tissues and other tissues innervated by post ganglionic 
adrenergic neurons. The rate of release of medullary hormones is responsible for the 
control of serum catecholamines. Thrombogenicity of catecholamines are due vari-
ous mechanisms including hypercoagulable states, endothelial damage, blood stasis 
and platelet aggregation. Oxidative stress generated by catecholamine excess causes 
coronary spasm, ultrastructural cell damage and arrhythmias. Elevated plasminogen 
activator inhibitor-1 during catecholamine excess causes hypercoagulability by hypofi-
brinosis. During stress, Catecholamines released in procoagulant environment causes 
vasoconstriction in adrenal veins resulting in venous thrombosis. Catecholamines 
generate moderately elevated levels of platelet count which enhances the risk of 
thrombosis. Hypercoagulability results in formation of coronary thrombus, rupture of 
atherosclerotic plaque and plaque progression due to gradual fibrinogen accumulation 
in the vessel walls. High levels of circulating catecholamines produce elevated levels 
thrombomodulin, the biomarkers of endothelial cell damage. In patients with hyper-
tension in catecholamine excess, resistance to blood flow and damage to the integrity 
of blood vessels lead to atherosclerosis. A case report has been discussed which sug-
gests an association of thrombotic tendency and catecholamine excess.
Keywords: catecholamines, thrombotic tendencies, atherosclerosis, 
hypercoagulation, platelet aggregation, endothelial damage, blood stasis
1. Introduction
Catecholamines are the class of neurotransmitters and hormones produced 
by the adrenergic nervous system, with a core structure of catechol and an amine 
group, regulating physiological processes [1]. Catechol refers to ortho-dihydroxy-
benzene and epinephrine and norepinephrine are the two major ethanolamine 
derivatives [2] occurring in the blood [3]. About 80% of epinephrine and 20% of 
norepinephrine are produced and released by the human adrenal medulla with a 
small amount of dopamine along with it [2].
1.1 Catecholamine biosynthesis
Catecholamines are synthesised and secreted from the chromaffin cells in 
adrenal medulla and sympathetic paraganglia [4]. Chromaffin granules produce 
catecholamines and fairly high concentration of adenosine triphosphate (ATP) and 
adenosine diphosphate (ADP) for active transport mechanism [2].
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Syntheses of catecholamines occur at two levels [5]:
1. Sympathetic nervous fibre extremities for norepinephrine.
2. Chromaffin cells of adrenal medulla for both epinephrine and norepinephrine.
Tyrosine hydroxylase is the rate limiting enzyme of catecholamine synthesis. 
Tyrosine from dietary proteins is transported to the brain and tyrosine hydroxylase 
(in the dopaminergic and noradrenergic neurons of CNS and in the non-neuronal 
cells of gastrointestinal tract and kidneys) converts it to 3,4-dihydroxyphenylala-
nine (DOPA). In the presence of aromatic L-amino acid decarboxylase, DOPA is 
converted to dopamine (DA) which is transported to vesicular storage granules. It 
may be released in the dopaminergic neurons or converted to norepinephrine in the 
noradrenergic neurons by dopamine beta-hydroxylase [6]. Norepinephrine is con-
verted to epinephrine by phenyl ethanolamine-N-methyltransferase (PNMT) [4].
Medullary hormones synthesised and stored in the chromaffin granules are a 
pool of ready to release hormones upon stimulation [7].
1.2 Catecholamine functions and receptors
Norepinephrine and epinephrine together contribute to an increase in cardiac 
output, heart-rate, respiration, blood pressure, blood flow to muscles, alertness 
and decrease in splanchnic and renal blood flow [2]. Norepinephrine alone causes a 
decrease in heart-rate indirectly as a result of reflex bradycardia because of vaso-
constriction effects [2].
Functions of catecholamines are mediated and regulated by alpha, beta adreno-
receptors and dopamine receptors. Each receptor located at distinct locations serves 
different functions and actions.
Alpha-1 receptors mediate adrenergic vasoconstriction [8]. Alpha-2 receptor 
stimulation causes inhibition of norepinephrine secretion [6]. Three subtypes of 
α2 receptors are α2A, α2B, and α2C. Alpha-2A in the peripheral postsynaptic region 
contributes to vasoconstriction in different vascular beds [8]. Beta-1 receptor 
stimulation causes positive inotropic and chronotropic action [6]. Beta-2 receptors 
stimulate vasodilation [9]. Beta 3 causes lipolysis in fatty cells and increase renin 
secretion [9].
Two types of dopamine receptors are D1 and D2.Stimulation of D1 receptors in 
coronary, renal, mesenteric and cerebrovascular beds causes vasodilation, diuresis 
and natriuresis. D2 receptor stimulation in presynaptic nerve endings causes inhibi-
tion of norepinephrine release [6].
1.3 Catecholamine metabolism
Neuronal catecholamines get metabolised intraneuronally after leakage from 
its stores [1]. Catecholamine metabolism mainly occurs in the liver [2]. There 
are two major catecholamine metabolites (i) metanephrines (constitutes 15% of 
urinary catecholamine) and (ii) vanillylmandelic acid, VMA (major end-point of 
norepinephrine and epinephrine metabolism [1] and constitutes 85% of excreted 
catecholamine) [2].
1.4 Catecholamine inactivation
Two major enzymes involved in the inactivation of catecholamines are catechol-
o-methyl transferase (COMT) and monoamine oxidase (MAO).COMT adds methyl 
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group to hydroxyl at 3-position of catechol ring and MAO catalyses oxidative 
deamination reaction [2].
Norepinephrine is inactivated by two processes (i) reuptake into the nerve 
terminals by the active carrier mechanism associated with Na+-K+-ATPase of which 
some part is stored to granular vesicles and the rest is metabolised and (ii) extra-
neuronal accumulation to vascular smooth muscles [10].
1.5 Catecholamine excess
The three distinct peripheral catecholamine systems are [11].
1. Sympathetic nervous system (SNS)
2. Adrenomedullary hormone system (AHS)
3. Dopamine autocrine/paracrine system (DOPA)
Sympathetic nervous system: the measure of norepinephrine release in the spe-
cific regions allows the clinical assessment of organ-specific sympathetic nervous 
tone and penetrating analysis of SNS in the pathophysiology of a disease state [12].
Adrenomedullary hormone system: the catecholamines stored in the chromaffin 
cells get released by innervations of preganglionic sympathetic fibres of splanchnic 
nerves and get dispersed after its entry to medulla [2].
Dopamine derived from plasma DOPA acts as an autocrine/paracrine substance. 
Human urine contains higher concentration of dopamine and its metabolites rather 
than norepinephrine and its metabolites as dopamine is generated in the non-
noradrenergic and non-adrenergic cells [13].
Catecholamines are distributed throughout the body including adrenal glands, 
chromaffin tissues and other tissues innervated by post ganglionic adrenergic neu-
rons [3]. The rate of release of medullary hormones is responsible for the control of 
serum catecholamines [2].
The cellular uptake and metabolism of catecholamines in the extraneuronal 
tissues and the exogenous administration of catecholamines together contribute 
to 25% of total metabolism of catecholamines produced in the SNS and adrenergic 
chromaffin cells [1].
During stressful conditions, the level of enzymes catalysing biosynthesis of 
catecholamines increase and enzymes degrading the catecholamines decrease [14]. 
Stress-induced changes in the adrenergic receptors occur due to the combination of 
neuronal and extraneuronal catecholamine uptake system, level of cAMP, density 
of adrenoceptor subtypes and coupling of agonist receptor complex with different 
G-proteins [14].
During chronic stress, increased levels of catecholamines produce aminolutins 
and oxyradicals. Oxidative stress thus generated causes coronary spasm, ultrastruc-
tural cell damage and arrhythmias [14]. They also cause Ca2+overload and cardiac 
dysfunction by acting on beta-1-adrenoceptor signal transduction pathway [14].
1.6 Catecholamine excess in pheochromocytoma
Catecholamine excess is seen in certain types of tumour such as pheochromo-
cytomas that are functional tumours of the chromaffin cells [15]. Norepinephrine 
secreting tumours are known to cause hypertension (in 80–90% of these patients 
[4]) and hypertensive crisis and their abrupt release may cause arrhythmias 
[6]. Of this nearly 40% of the patients suffer from sustained hypertension 
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1.6 Catecholamine excess in pheochromocytoma
Catecholamine excess is seen in certain types of tumour such as pheochromo-
cytomas that are functional tumours of the chromaffin cells [15]. Norepinephrine 
secreting tumours are known to cause hypertension (in 80–90% of these patients 
[4]) and hypertensive crisis and their abrupt release may cause arrhythmias 
[6]. Of this nearly 40% of the patients suffer from sustained hypertension 
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(norepinephrine secreting tumours), 45% from paroxysmal hypertension (epi-
nephrine secreting tumours) and 5–15% from normotension (dopamine secreting 
tumours) [4].
Other vasoactive substances like neuropeptide Y, adrenomedullin and atrial 
natriuretic peptide contribute to hypertension in these patients [6]. Neuropeptide 
Y increase coronary and peripheral vascular resistance and potentiate norepineph-
rine-induced vasoconstriction [7].
Pheochromocytoma produces enormous amounts of catecholamines due to 
mutation of succinate dehydrogenase by oxidative phosphorylation deficit [6].Two 
major mechanisms in pheochromocytoma that leads to catecholamine excess are 
translocation of dopamine into storage granules and the presence of dopamine beta 
hydroxylase enzyme [1].
In extra-adrenal tumours, norepinephrine levels are high, in adrenal tumours 
both norepinephrine and epinephrine are in excess and in multiple endocrine 
neoplasia type 2 and neurofibromatosis type 1, epinephrine levels are high [6].
In non-functional/silent pheochromocytoma, metanephrine levels are elevated 
instead of catecholamines [6].
Complication of pheochromocytoma in hypertensive crisis are sustained 
hypertension by continuous elevated levels of catecholamine causing vasoconstric-
tion and orthostatic hypertension due to reduced blood volume that resulting in 
vasoconstriction, postural tachycardia and postural hypotension [4].
Neurological complications are hypertensive encephalopathy, haemorrhage (due 
to paroxysmal hypertension) and acute ischemic stroke (due to postural hyperten-
sion) [4].
In 78% of pheochromocytoma patients, thrombus exists at the time of their 
tumour discovery and 75% of the secondary thrombi are located in inferior vena 
cava or heart or both [16]. Venous thromboembolism and acute arterial thrombi 
are well described in such patients [17] but evidence of stroke, aortic thrombi and 
myocardial infarction are fewer [18].
Several mechanisms explain thrombotic tendencies in pheochromocytomas by 
elevated catecholamines:
• Catecholamines generate moderately elevated levels of platelet count which 
enhance the risk of thrombosis [19].
• Platelet aggregation is increased in pheochromocytoma [18] and produce 
thrombi in low-flow areas causing coronary events [19].
• Contributing factors to thrombus formation are erythropoietin, pro-coagula-
tion and serotonin [6].
• Catecholamine excess in other tumours like paragangliomas may cause ADP-
mediated platelet aggregation leading to thrombotic events [20].
• During stress, catecholamine release in procoagulant environment causes 
vasoconstriction in adrenal veins resulting in venous thrombosis [21].
• Loss of antithrombin III in glomerular diseases associated with hypertension 
may increase thrombotic risk [22].
• Pheochromocytoma causes thrombosis of caudal vena cava and aortic throm-
boembolism through Virchow’s triad list [20, 22]:
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Mortality of pheochromocytoma patients occur due to either acute intramyocar-
dial necrosis or diffuse patchy myocardial fibrosis [23].
2.  Mechanisms associated with thrombus formation in catecholamine 
excess
Thrombus formation and dissolution are physiological processes with dynamic 
balance between procoagulation and anticoagulation mechanism [24]. Catecholamine 
excess contributes to long-term development of atherosclerosis and cardiovascular 
risk [25] due to their effect on carbohydrate and lipid metabolism [23].
3. Cascade of thrombus formation
Thrombotic process occurs by the activation of coagulation cascade in different 
phases [26].
1. Initiation phase—the extrinsic pathway of coagulation in which low amounts 
of active pro-coagulant factors are produced.
2. Amplification phase—level of coagulation factors increase.
3. Propagation phase—active coagulation factors are generated like thrombin 
which binds to phospholipid at the surface of activated platelets.
4. Stabilization phase—thrombin provides strength and stability to growing clot 
and thrombin activatable fibrinolysis inhibitor.
Injury to the vessel walls due to resistance, in catecholamine excess states, 
causes exposure of glycoprotein tissue factor (TF) to the blood. After exposure, 
TF bind to Factor VII/VIIa and forms tertiary complex in the presence of calcium 
to activate factor X to Xa, factor IX to IXa and factor VIIa. At the site of injury, 
platelet activation, conversion of fibrinogen to fibrin and thrombus formation 
occurs. Platelets are able to regulate their gene and protein expression for binding 
to sub endothelium [26].
Diseases affecting Virchow’s triad can induce clot formation [27].
4. Hypercoagulability
Hypercoagulability is the tendency to produce thrombosis by inherited or 
acquired molecular defects. Thrombus is formed based on the number of predispos-
ing factors and environmental stress [13].
Cancer is the second major cause of hypercoagulation with clinical thrombosis 
in 15% and thrombosis on autopsy in 50% patients [28].
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Catecholamines increase plasminogen activator inhibitor-1 (PAI-1) mRNA by 
expression of PAI-1 genes in the cardiovascular system by neurological and neuro-
endocrine mechanisms via beta-adrenoreceptors [29]. PAI-1, a member of serine-
protease inhibitor, inhibits both tissue type and urinary-type plasminogen activator. 
Elevated PAI-1 during catecholamine excess causes hypercoagulability by hypofi-
brinosis. High levels of PAI-1 act on adipokines in the atherogenic process and cause 
atherosclerotic lesions and atheromas [30]. Epinephrine regulates Beta-mediated 
tissue-type plasminogen activator to produce an increase in fibrinolytic capacity [25].
Antithrombin III (AT-III) inhibits the protein-splitting reaction, characteristic 
of haemostasis, by interfering with the activity of four of the serine proteases 
and antagonising thrombin [31]. Hypertension associated glomerular diseases 
in catecholamine excess may cause loss of AT-III by protein loss in the urine. 
Hypoalbuminemia and hypercholesterolemia in Proteinuria causes platelet hyper-
aggregability and aggravate hypercoagulability. Increased levels of fibrinogen and 
thromboxane in protein-losing nephropathy contribute to thrombosis [27].
Hypercoagulability result in formation of coronary thrombus, rupture of ath-
erosclerotic plaque and plaque progression due to gradual fibrinogen accumulation 
in the vessel walls [24].
In patients with borderline hypertension, coagulation activation occurs before 
clinical manifestations of vascular damage appear [32].
5. Platelet aggregation
In thrombus formation, a high proportion of platelets translocates from their 
initial point of attachment to the injured vessel wall and forms a firm adhesion 
contact [31]. Catecholamine infusion induces platelet aggregation in ex-vivo 
and animal models [16]. They activate platelets by interacting with platelet 
α2-adrenoreceptor in in-vitro studies. Stimulation of α1-adrenoreceptor inhibits 
platelet aggregation by inactivating platelet response to epinephrine [25]. In-vivo 
adrenergic infusion causes platelet activation and an increase in platelet size, 
aggregation and releasing factors [24]. Elevated factor V: C, factor VIII: C, v 
Willebrand Factor: Ag, tissue-plasminogen activator (t-PA): Ag, contribute to risk 
of atherothrombotic events [25]. Redistribution of cardiac blood flow in catechol-
amine infusion causes regional slowing of blood flow and enhanced tendency for 
intravascular platelet aggregation [23].
The anticoagulative effect of epinephrine is explained by a 50% decrease in 
the ratio of maximal coagulation activation and maximal fibrinolytic activa-
tion by decreased tumour necrosis factor (TNF) and interleukin (IL) 10 [33]. 
Epinephrine induce fibrinogen receptor exposure and fibrinogen binding to 
potentiate platelet aggregation. Epinephrine infusion causes short-term recruit-
ment of platelets and functionally active Factor VIII from the spleen for thrombus 
formation. They discharge high molecular von Willebrand Factor (vWF) which 
increase the activity of platelet adhesion from its storage compartments. Elevated 
epinephrine levels increase platelet deposition on the atherosclerotic vessels with 
high local shear rate [25].
Norepinephrine activates platelet aggregation in-vivo by stimulating 
α2-adrenoreceptor [24].
It causes platelet aggregation in two phases [16]:
• Initial reversible aggregation.
• Simulated release of adenosine diphosphate.
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Norepinephrine initiates platelet thrombosis by directly damaging the endothe-
lial walls of vessels and breaking its integrity [24]. In acute mental stress, 60% of 
variation in thrombin formation depends on amount of norepinephrine secreted 
and sensitivity of β2-adrenergic receptor [19].
6. Clotting time
Adrenergic activation by epinephrine injection increases factor VIII: C and cause 
a decrease in clotting time. In-vivo adrenergic infusion stimulate β-2 adrenergic 
vascular receptors to release clotting factors like FVIII, v WF, and t-PA from endo-
thelium to the circulation [24] resulting in thrombotic risk in both coronary artery 
disease and hypertension [25].
7. Endothelial damage
Endothelium maintains balance between prothrombotic and atherothrombotic 
tendencies [27]. Endothelial cells provide a non-thrombogenic surface that inhibits 
platelets and blood cells from adhering and activating coagulation cascade [34]. 
Antithrombotics like thrombomodulin, heparin sulfate, tissue factor pathway 
inhibitor and protein S are involved in reducing the activation of AT III and protein 
c to elevate antithrombotic tendencies. Synthesis and induction of prothrombotic 
mediators such as tissue factor and antifibrinolytic factors like PAI-1 take part in 
prothrombotic tendencies [27].
Disproportion in the tendencies causes endothelial damage where suben-
dothelial proteins are exposed and favour platelet adhesion [27]. According 
to Gando et al. [35], endothelial damage can occur due to both exogenous and 
endogenous release of catecholamines. High levels of circulating catecholamines 
produce elevated levels thrombomodulin, the biomarkers of endothelial cell 
damage [36]. Due to loss of endothelial cell protection and expression of pro-
coagulant and prothrombotic molecules, platelets adhere to the subendothelial 
surface and release ADP and thromboxane A2 causing imbalance in haemostasis 
and thrombosis [37].
8. Blood stasis
Blood stasis plays an important role in the formation of thrombus. Thrombus 
forms in regions of blood stasis like narrow artery due to atheromatous plaque, 
mechanical vasoconstriction, prolonged immobilisation and varicose vein. From 
the injured tissue, tissue thromboplastin produced causes initial thrombus forma-
tion followed by platelet activation by thrombin. Thrombin transforms fibrinogen 
to insoluble fibrin and release to stagnant blood [36].
In patients with hypertension in catecholamine excess, resistance to blood flow 
and damage to the integrity of blood vessels lead to atherosclerosis [27, 32]. Three 
mechanisms explain the overall increased vascular resistance [37]:
(i) Rarefaction of arterioles and capillaries.
(ii) Reduced internal diameter of arterioles.
(iii) Increase in arterial and arteriolar wall mass.
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The significant role of sympathetic nervous system in elevated haemostatic activ-
ity in atherosclerosis and thrombus formation explains the role of catecholamines in 
cardiovascular diseases and associated arterial thrombus formation [25]. The factors 
associated with thrombosis in different mechanisms are summarised in Table 1.
9. Management of thrombosis
Hypertension associated with catecholamine excess plays an important role in 
the thrombus formation by mechanisms explained above. So treatment for hyper-
tension is the primary objective in treatment and prevention of thrombotic tenden-
cies. The most preferred antihypertensive is phenoxybenzamine which is an alpha 
and beta receptor antagonist given at 10 mg once a day with gradual dose titration 
to 30 mg three times a day. Appropriate anti-coagulation with heparin is vital for 
patients with risk of thrombosis to prevent devastating outcomes [19].
Removal of tumours producing excess catecholamines play a crucial role in alle-
viating symptoms associated with hypertension and thus thrombus formation. Due 
exaggerated fall in blood pressure after surgical removal of these tumours, adequate 
vascular volume replacement with oral fluids and salt is recommended [38].
Here in a case report has been discussed which suggests an association of throm-
botic tendency and catecholamine excess.
10. Case report
A Case report on cerebral venous thrombosis due to pheochromocytoma in a 
patient with Von Hippel Lindau (VHL) mutation [39] explains an unusual connec-
tion between thrombosis and pheochromocytoma in a 15 year old boy with pheo-
chromocytoma and associated hypertension. The patient was primarily presented 
with cerebral venous thrombosis and seizures. Initial examination revealed left 
S. No. Mechanism of thrombosis Factors involved in thrombosis




2. Platelet aggregation 1. Factor V: C
2. Factor VIII: C
3. v Willebrand factor (v WF)
4. t-PAI-1
5. Tumour necrosis factor (TNF)
6. Interleukin 10 (IL-10)
3. Clotting time 1. Factor VIII:C
2. (v WF)
3. t-PAI-1
4. Endothelial damage 1. t-PAI-1
2. Thrombomodulin
3. Thromboxane A2
5. Blood stasis 1. Thromboplastin
2. Thrombin
Table 1. 
Summary of factors associated with thrombosis.
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frontoparietal hematoma and superior sagittal and transverse sinus thrombus for 
which he was treated with heparin and antiepileptics. Follow-up showed elevated 
blood pressure and high urine catecholamine levels. The diagnosis of abdominal 
mass after evaluation for consistent elevated blood pressure turned out to be pheo-
chromocytoma. He underwent para-aortic dissection and right adrenalectomy.
VHL disease is an autosomal, dominant inherited tumour syndrome which 
occurs as a result of a germline mutation in the VHL gene. Even though its associa-
tion with pheochromocytoma is under-studied, VHL proteins are found to cause 
tumorigenesis in pheochromocytoma by induction of either gain of function, 
dominant negative effect or gene dosage effect in chromaffin cells [40].
Some mechanisms are established to explain the association of Catecholamine 
excess in pheochromocytoma and thrombus formation:
1. Tumours produce different chemicals with prothrombotic nature that cause 
hypercoagulability as a paraneoplastic feature [41]. The release of proco-
agulants, fibrinolytics and proteolytic factors induce thrombosis. Neoplastic 
vascular invasion damages the thromboresistant properties of vessel wall and 
tumour cell attachment to the endothelial surface leading to endothelial retrac-
tion and exposure of basement membrane. The damaged endothelial cells and 
matrix cause platelet adhesion and aggregation by release of procoagulatory 
and antagonistic substances [42].
2. Adrenal tumours release excess catecholamines and cause thrombophilia and 
clot formation [16].
3. In the case of VHL mutation, certain changes are produced in the Hypoxia 
inducible factor (HIF) resulting in polycythaemia and increased venous 
thrombosis [43]. HIF regulates both oxygen hemostasis and erythropoietin 
receptor expression [44, 45].
To associate hereditary disorders with thrombosis in excess catecholamine state 
is restricted because of unavailability of literatures explaining the same. Excess 
catecholamines themselves produce thrombosis even though an inherent mutation 
of VHL was found in the above patient as a cause of thrombosis. Hypertension 
associated with high catecholamine levels make a patient more prone to thrombosis 
than others with normal blood pressure. In patients with tumours such as pheochro-
mocytoma and paraganglioma, there is high catecholamine levels which increase 
the risk of thrombotic tendencies compared to other patients with catecholamine 
excess alone.
11. Conclusion
Though there have been evidences of thrombus formation after infusion of 
catecholamines in animals and humans, available evidence of the exact mechanism 
of thrombotic tendencies is scanty. Catecholamine excess states are a diagnostic 
challenge due to heterogenous clinical presentation like fluctuating hyperten-
sion in young which may not attract enough clinical and laboratory attention. 
Thrombogenicity of catecholamines are due various mechanisms including 
hypercoagulable states, endothelial damage, blood stasis and platelet aggregation. 
Surgical removal of tumours associated with catecholamine excess provide a clinical 
approach in treating abnormalities of thrombus formation.
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1. Tumours produce different chemicals with prothrombotic nature that cause 
hypercoagulability as a paraneoplastic feature [41]. The release of proco-
agulants, fibrinolytics and proteolytic factors induce thrombosis. Neoplastic 
vascular invasion damages the thromboresistant properties of vessel wall and 
tumour cell attachment to the endothelial surface leading to endothelial retrac-
tion and exposure of basement membrane. The damaged endothelial cells and 
matrix cause platelet adhesion and aggregation by release of procoagulatory 
and antagonistic substances [42].
2. Adrenal tumours release excess catecholamines and cause thrombophilia and 
clot formation [16].
3. In the case of VHL mutation, certain changes are produced in the Hypoxia 
inducible factor (HIF) resulting in polycythaemia and increased venous 
thrombosis [43]. HIF regulates both oxygen hemostasis and erythropoietin 
receptor expression [44, 45].
To associate hereditary disorders with thrombosis in excess catecholamine state 
is restricted because of unavailability of literatures explaining the same. Excess 
catecholamines themselves produce thrombosis even though an inherent mutation 
of VHL was found in the above patient as a cause of thrombosis. Hypertension 
associated with high catecholamine levels make a patient more prone to thrombosis 
than others with normal blood pressure. In patients with tumours such as pheochro-
mocytoma and paraganglioma, there is high catecholamine levels which increase 
the risk of thrombotic tendencies compared to other patients with catecholamine 
excess alone.
11. Conclusion
Though there have been evidences of thrombus formation after infusion of 
catecholamines in animals and humans, available evidence of the exact mechanism 
of thrombotic tendencies is scanty. Catecholamine excess states are a diagnostic 
challenge due to heterogenous clinical presentation like fluctuating hyperten-
sion in young which may not attract enough clinical and laboratory attention. 
Thrombogenicity of catecholamines are due various mechanisms including 
hypercoagulable states, endothelial damage, blood stasis and platelet aggregation. 
Surgical removal of tumours associated with catecholamine excess provide a clinical 
approach in treating abnormalities of thrombus formation.
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